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Interleukin-1β (IL-1β) is a key mediator in the inflammatory response essential to cellular
defense against pathogen invasion and to the repair of tissue damage. While some
studies suggest that IL-1β signaling is harmful to the injured central nervous system,
others report neuroprotective effects that appear to be context-dependent. Previously,
the Hewett laboratory demonstrated the importance of IL-1β-mediated increases in the
cystine-glutamate transporter, system xc-, as a novel contributor to inflammatory hypoxic
neuronal injury, a model of the ischemic penumbra. The main focus of this doctoral
research was to elucidate the specific cell type(s) in mixed cortical cultures that respond
to IL-1β by enhancing the activity of system xc-, the molecular mechanism by which this
occurs, and the physiological and pathophysiological consequences of this regulation.
IL-1β exposure (0.1-3 ng/ml) enhances expression of the substrate-specific light chain of
system xc-, xCT, in pure astrocyte cultures in a time-dependent manner. By utilizing
pharmacological inhibitors and cells derived from animals harboring a mutation in the
Slc7a11 gene (sut mice) that encodes for xCT, we now provide definitive evidence that
alterations in system xc- activity in astrocytes exclusively mediate the potentiation of

hypoxic neuronal injury by IL-1β and initiates hypoglycemic neuronal injury. Additionally,
the neuronal cell death in these paradigms is non-cell autonomous. Even though the IL1β-mediated enhanced efflux of glutamate, which occurs by virtue of its obligate
exchange, can be deleterious, cystine import via system xc- is critical for the synthesis of
the antioxidant glutathione (GSH). Since astrocytes function as the predominant provider
of GSH in the CNS, we assessed whether IL-1β treatment altered astrocyte GSH levels.
Pure cortical astrocyte cultures treated with IL-1β (3 ng/ml) exhibit a time-dependent
increase in extracellular GSH levels, suggesting both enhanced synthesis and export
that is associated with protection against oxidative stress in pure astrocyte cultures as
well as mixed cultures exposed to tert-butyl hydroperoxide (tBOOH; 0.1-1.5 mM). Hence,
IL-1β may be an important stimulus for increasing astrocytic GSH production, and thus,
total antioxidant capacity in the brain. These findings unequivocally demonstrate that IL1β and astrocytic system xc- contribute to neuronal injury and neuroprotection in a
context-dependent manner.
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CHAPTER 1

General principles

1

1.1

Introduction
Inflammation is an intrinsically complex biological response mounted to

combat pathogen invasion, protect against tissue damage and promote tissue
repair. However, unabated inflammation can be deleterious and contribute to
injury and pathology. Given that inflammation is a fundamentally protective
response, it should not be surprising that inflammatory mediators can exert
beneficial effects. This dissertation focuses specifically on the pleiotropic
cytokine, interleukin-1β (IL-1β) described by some as “the master regulator of
neuroinflammation” (Basu et al., 2004), and the ability of IL-1β to contribute to
neuronal injury under conditions of energy deprivation and protect neurons
against oxidative stress-induced injury via its regulation of an amino acid
exchanger known as system xc- which transports the amino acids cystine and
glutamate.

1.2

Glutamate
Glutamate is the major excitatory neurotransmitter in the CNS (Fonnum,

1984). It is involved in developmental processes such as cell migration and
differentiation, and also in most physiological processes in the brain including
learning and memory via its interaction with AMPA and NMDA receptors, and
energy metabolism, by serving as a precursor to α-ketoglutarate. Regulated
control of glutamate release and efficient uptake of this transmitter are required
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for glutamatergic signaling under physiological conditions. In the event of
dramatic enhancements in extracellular glutamate, the prolonged stimulation of
glutamate receptors can initiate cell death via a process termed excitotoxicity
(see section 1.2.4).
1.2.1 Glutamate Physiology
Glutamatergic neurons make up 90% of all neurons in the brain
(Dingledine and McBain, 1999). In this subset of neurons, glutamate is packaged
in synaptic vesicles and released via exocytosis upon depolarization of the nerve
terminals. Once released, glutamate either binds to its receptors, diffuses away
from the synapse, or is cleared from the synapse via excitatory amino acid
transporters (EAAT1-5 also known as system XAG-) which are localized to both
neurons and astrocytes. Notably, astrocytic glutamate uptake via EAAT1/ GLAST
and EAAT2/Glt-1 is the predominant route of glutamate clearance, with Glt-1
responsible for clearance of 80% of glutamate in the hippocampus (Lehre and
Danbolt, 1998). Glutamate that is internalized via astrocytic transporters can be
converted to glutamine via the action of glutamine synthetase, an enzyme
localized exclusively to astrocytes (Norenberg and Martinez-Hernandez, 1979).
Conversion of glutamate to glutamine enables synaptically released glutamate to
be recycled and shuttled back to neurons in a non-neuroactive form. Within the
neuron glutamine is converted back to glutamate via glutaminase. Alternatively,
glutamate can be converted to α-ketoglutarate, a key intermediate in the Kreb’s
cycle, via the enzymatic action of glutamate dehydrogenase or glutamate
oxaloacetate transaminase.
3

1.2.2 Glutamate Signaling
Glutamate binds to two distinct classes of receptors, ionotropic and
metabotropic receptors. Ionotropic receptors flux cations following glutamate
binding, whereas metabotropic receptors activate intracellular signaling via Gprotein-coupled second messenger systems. There are three types of ionotropic
receptors named according to agonist pharmacology: the N-methyl-D-aspartate
(NMDA) receptor, the α-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) receptor,
and the kainate receptor. Additionally there are 8 metabotropic receptors which
are separated into three groups based on sequence homology, second
messenger systems, and pharmacological agonist and antagonist profiles. Group
I metabotropic glutamate receptors consist of mGluR1 and mGluR5 and typically
activate phospholipase C pathways and increase intracellular Ca2+. Group II
(mGluR2 and mGluR3) and Group III (mGluR4, mGluR6, mGluR7, and mGluR8)
metabotropic receptors generally reduce adenylate cyclase activity [ for a
detailed review see (Nakanishi et al., 1998; Dingledine et al., 1999; Featherstone
and Shippy, 2008; Kim et al., 2008)].

1.2.3 Basal ambient extracellular glutamate
At its most basic level, ambient glutamate levels are dictated by the rate of
release and the rate of glutamate clearance from the extracellular space. To fully
appreciate ambient extracellular glutamate levels, one must first understand
glutamate compartmentalization within the CNS. Neurons and astrocytes have
4

millimolar concentrations of intracellular glutamate, with neurons having higher
levels of cytosolic glutamate due to the action of glutamine synthetase in
astrocytes which converts glutamate to glutamine (Nedergaard et al., 2002). The
concentration of glutamate in the cytosol of glutamatergic neurons can reach 10
mM, with an estimated glutamate concentration of up to 100 mM in the synaptic
vesicles (Riveros et al., 1986; Burger et al., 1989; Clements et al., 1992; Ottersen
et al., 1992; Danbolt, 2001). Extracellular glutamate levels in the synapse
fluctuate as a function of neuronal activity and range from 2 µM – 1 mM
(Meldrum, 2000; Danbolt, 2001).
Numerous techniques have been employed to estimate extracellular
glutamate levels in the brain with concentrations estimated to range between ≈25
nM to 5 µM (Danbolt, 2001; Baker et al., 2002b; Baker et al., 2003; Cavelier and
Attwell, 2005; Nyitrai et al., 2006; Herman and Jahr, 2007) depending on the
particular area analyzed and technique employed. For example, in vivo
microdialysis measurements of extracellular glutamate levels range from 1-2 µM
in the striatum (Rothstein et al., 1996; Baker et al., 2002b) to 5 µM in rat nucleus
accumbens (Baker et al., 2002b; Baker et al., 2003). Importantly, micromolar
concentrations of glutamate could activate glutamate receptors as the EC50 of the
NMDA receptor for glutamate is 2 µM (Patneau and Mayer, 1990; Herman and
Jahr, 2007). AMPA/kainate receptors are activated by glutamate at much higher
concentrations and thus are not likely to be activated by ambient levels of
extracellular glutamate (for EC50 values for other glutamate receptors see Table
1). Alternatively, micromolar concentrations of glutamate could cause receptor
5

desensitization and the suppression of glutamate signaling. Sather and
colleagues desensitized ≈80% of NMDA receptors with 1 µM glutamate in
outside-out patches from embryonic mouse neurons (Sather et al., 1992).
AMPA/kainate receptors desensitize at concentrations ranging from 3 – 13 µM
(Featherstone and Shippy, 2008), making it possible that some subset of
ionotropic glutamate transporters are tonically desensitized by ambient
glutamate.
It is possible that microdialysis studies overestimate extracellular
glutamate concentrations as the insertion of the microdialysis probe damages
tissue, creates an artificial space surrounding the probe and in turn increases the
distance between the probe and functional transporters (Benveniste and
Huttemeier, 1990). Herman and Jahr measured currents produced by application
of NMDA and glutamate in rat CA1 pyramidal neuronal slices and estimated a
value of ≈25 nM ambient extracellular glutamate (Herman and Jahr, 2007).
Since glutamate is rapidly taken up by the EAATs, the EC50 values obtained from
dose-response curves for NMDA and glutamate were compared to create a
conversion factor which was utilized to estimate ambient glutamate. The authors
contend that ambient glutamate levels maintained at nanomolar concentrations
would prevent NMDA receptor activation / desensitization (Herman and Jahr,
2007).

6

ED50 of glutamate on glutamate
receptors (µM)
NMDA
AMPA
Kainate
mGluR1
mGluR2
mGluR3
mGluR4
mGluR5
mGluR6
mGluR7
mGluR8

2-3
200-500
300-800
9-13
4-20
4-5
3-20
3-10
16
1000
0.02

Table 1. ED50 values for glutamate activation of glutamate receptors. Values
obtained from (Conn and Pin, 1997; Meldrum, 2000; Featherstone and Shippy,
2008).

Based on analysis of the stoichiometric transport of the anionic form of
glutamate, 3 Na+, and 1 H+ and the counter transport of 1 K+ in EAAT3
transfected oocytes, EAAT / system XAG- transporters are predicted to have the
capacity to theoretically reduce extracellular glutamate to ≈ 2 nM (Zerangue and
Kavanaugh, 1996). Yet, only one study has calculated extracellular glutamate to
lie near this theoretical lower limit (Herman and Jahr, 2007). Naturally, it raises
the question of the true concentration of ambient glutamate and the source(s)
maintaining glutamate levels 4in the extracellular compartment.
Inhibition of glutamate uptake by the application of DL-threo-betabenzyloxyaspartate (TBOA) in organotypic hippocampal slices results in
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increased extracellular glutamate. This glutamate is not synaptically released,
and is not dependent on Na+ and Ca2+ (Jabaudon et al., 1999). Further,
increasing levels of astrocytic intracellular glutamate via inhibition of glutamine
synthetase enhances glutamate accumulation following inhibition of glutamate
uptake suggesting a glial source (Jabaudon et al., 1999).
Application of cystine (1 mM) to cerebellar and cortical slices produces an
inward, glutamate dependent current in Purkinje and pyramidal cells and the
hypothesis that a cystine-glutamate exchanger regulates extracellular glutamate
levels emergedd (Warr et al., 1999). Additional supportive evidence was noted in
microdialysis studies in the striatum. Reverse dialysis of a cystine-glutamate
transporter antagonist reduces extracellular glutamate by 60% (Baker et al.,
2002b). Further, the function of this transporter is conserved across species as
genetic disruption of the same cystine-glutamate transporter via insertion of a
mutation in the first exon of the genderblind (gb) gene in Drosophila produces a
50% reduction in extracellular glutamate (Augustin et al., 2007).
Importantly, basal extracellular glutamate levels dictate the density of
post-synaptic ionotropic glutamate receptor clustering in Drosophila. Mutant
genderblind Drosophila with reduced ambient glutamate levels have increased
glutamate receptor immunoreactivity and enhanced spontaneous excitatory
currents at the neuromuscular junction (Augustin et al., 2007). Glutamate
receptor density was restored with physiological levels of glutamate (Augustin et
al., 2007). Additionally, ambient basal extracellular glutamate tonically activates
mGluR2/3 receptors

to negatively modulate glutamatergic and dopaminergic
8

signaling in the striatum and nucleus accumbens (Baker et al., 2002b; Moran et
al., 2005). Interestingly, cocaine administration reduces extracellular glutamate in
the rat nucleus accumbens and this alteration in glutamatergic tone is associated
with drug-seeking behavior (i.e. susceptibility to relapse) following cocaine
withdrawal (Baker et al., 2002b; Kalivas, 2009).

1.2.4 Glutamate Excitotoxicity
Extracellular glutamate levels must be carefully regulated as prolonged
stimulation of its cognate receptors will lead to neuronal cell death. The concept
of excitoxicity is described as the excessive and toxic activation of excitatory
amino acid receptors that culminates in cell death (Olney, 1969; Choi, 1992).
Normally, glutamate concentrations in the extracellular space are maintained at
low levels, however, if levels rise dramatically as a result of increased release or
an impairment in the clearance of glutamate, a calcium-dependent cascade is
initiated (Sattler and Tymianski, 2001). Ultimately, the prolonged activation of
glutamate receptors enhances Na+ and Ca2+ flux into the cells (Figure 1.1). The
ensuing Ca2+ dysregulation activates kinases, proteases, and lipases, and
increases the production of reactive oxygen and nitrogen species which impairs
mitochondrial function and results in cell death [reviewed extensively in (Choi,
1988; Sattler and Tymianski, 2000, 2001)].
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Figure 1.1. Mechanisms of excitotoxicity. High levels of glutamate
activate the AMPA receptor, inducing sodium (and calcium)) influx and
neuronal depolarization. Depolar
Depolarization induces the release of Mg
M 2+
from the NMDA receptor which is activated by the binding of glutamate
and its co-agonist
agonist glycine to flux sodium and calcium. Volta
Voltagedependent calcium channels (VDCC
(VDCC)) are also activated. Intracellular
calcium
dramatically
increases
and
activates
proteases,
phospholipases, and nucleases, and induces the production of free
radicals and reactive species. Ultimately the cascade leads to cell
death. Modified from (Camacho and Massieu, 2006)
2006).
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1.2.6 Sources of extracellular glutamate
Glutamate originating in neurons can be released via exocytosis following
depolarization or as a consequence of cell lysis. Glutamate is released from
astrocytes via Ca2+-dependent and Ca2+-independent processes (Parpura et al.,
1994; Araque et al., 1998; Jabaudon et al., 1999). Astrocytes express several
proteins required for exocytosis including synaptobrevin II and syntaxin (Parpura
et al., 1994; Parpura et al., 1995; Araque et al., 1998), and ligands such as
prostaglandin E2, ATP, glutamate, and bradykinin are known to induce glutamate
release (Parpura et al., 1994; Bezzi et al., 1998; Jeremic et al., 2001). Further,
the reverse operation of glutamate transporters (system XAG-) could enhance
extracellular glutamate levels (Nicholls and Attwell, 1990; Szatkowski et al.,
1990; Longuemare and Swanson, 1995), however this likely only operates under
pathological conditions when the Na+ and K+ gradient across the plasma
membrane is reduced such as occurs under cerebral ischemic conditions.
Glutamate efflux can arise as a consequence of activation of volume sensitive
organic anion channels as a component of volume regulation (Kimelberg et al.,
1990; Longuemare et al., 1999; Liu et al., 2006). Interestingly, inhibition of a
VSOAC with 5-nitro-2-3-phenylpropylamino benzoate (NPPB) can attenuate
receptor-mediated glutamate release from astrocytes (Jeremic et al., 2001).
Other sources of glutamate release include: P2X7 channels (Duan et al., 2003),
hemichannels (Ye et al., 2003; Takeuchi et al., 2006), and system xc- (Warr et al.,
1999), however this dissertation is particularly interested in release of glutamate
via system xc-, and as such will focus on the cystine-glutamate exchanger as the
11

primary source of the excitotoxic levels of extracellular glutamate observed in the
paradigms described herein.

1.3

System xcSystem xc- was first identified in 1980 in the IMR-90 human fibroblast cell

line as a sodium-independent electroneutral transporter of the amino acids
cystine and glutamate (Bannai and Kitamura, 1980). Cystine and glutamate both
significantly decrease transport of each other, whereas minimal inhibition of
cystine and glutamate transport by other amino acids is observed, demonstrating
the specificity of the transporter. The Km for cystine is reported as 40-50 µM in
fibroblasts (Bannai and Kitamura, 1980) which is consistent with the value of ≈ 30
µM obtained for cystine in the mixed cortical cultures routinely used in our
laboratory (Fogal et al., 2007). The import of cystine via system xc- is directly
coupled to glutamate export, occurring in a Na+-independent, Cl--dependent
manner with 1:1 stoichiometry (Bannai, 1986). Further, transport is limited to the
anionic forms of these amino acids with exchange being electroneutral.
System xc- is a member of the heteromeric amino acid transporter family in
which transporters consist of a heavy and light subunit joined via an extracellular
disulfide bond (for a detailed review see (Chillaron et al., 2001)). With respect to
system xc-, xCT is the light chain that confers substrate specificity, and 4F2hc
(heavy chain of the 4F2 surface antigen also known as CD98) is the heavy chain
that is thought to target the transporter to the plasma membrane (Sato et al.,
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1999; Bassi et al., 2001). Alternatively, xCT can interact with RBAT (related to
the bo,+ amino acid transporter), an alternate heavy chain to produce a functional
transporter in experimental systems in which the cDNA of both subunits is
injected into Xenopus oocytes (Bassi et al., 2001). However, it remains to be
determined if this interaction occurs naturally in vivo.
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Figure 1.2.. Structure of system xc- amino acid transporter. System
xc- is a heteromeric amino acid transport system consisting of two
subunits: xCT (white) -- the light chain that confers substrate specificity
-- and a heavy chain (4F2hc depicted; black) or RBAT -- that is thought
to target the transporter to the plasma mem
membrane (Sato et al., 1999;
Bassi et al., 2001).. The subunits are joined via an extracellular disulfide
bond. The import of cystine via system xc- is directly coupled with
glutamate export, occurring in a Na+-independent, Cl--dependent
dependent
manner with 1:1 stoichiometry (Bannai, 1986). Adapted from (Danbolt,
2001; Shih et al., 2006)
2006).
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1.3.1 Structure of system xcThe light subunit of system xc- , xCT, was first identified and cloned by
Sato and colleagues in 1999 from mouse peritoneal macrophage cells (Sato et
al., 1999). Later, human xCT was identified (Sato et al., 2000; Bassi et al., 2001;
Kim et al., 2001) with full length human xCT cloned from an undifferentiated
human teratocarcinoma cell line. The human xCT gene, also known as solute
carrier family 7 member 11 (Slc7a11), is located on chromosome 4q28-31, and
produces a 501 amino acid protein which shares 89% sequence identity and 9396% similarity with the 502 amino acid-containing mouse xCT (Bassi et al., 2001;
Bridges et al., 2001). An additional truncated xCT clone thought to be a splice
variant has been observed, but its function remains to be determined (Sato et al.,
2000; Kim et al., 2001). As shown in Figure 1.2, xCT has 12 putative membrane
spanning domains, with both the N- and C-

termini localized intracellularly

(Gasol et al., 2004). Structural data remains elusive with respect to the location
of substrate binding. Gasol and colleagues believe that substrate binding occurs
within loops 2 and 3 as biotinylation of His110 does not occur in the presence of
the system xc-

substrates cystine and glutamate, or the non-transportable

system xc- inhibitor (S)-4-carboxyphenylglycine (4-CPG) (Gasol et al., 2004). The
same group found that the 8th putative transmembrane domain close to Cys327
also participates in substrate binding and /or permeation (Jimenez-Vidal et al.,
2004). Traditionally, the light subunits of the Slc7 family are not glycosylated,
although species-specific differences in glycosylation are reported as human xCT
possesses a site for N-linked glycosylation (Asn314) in the extracellular loop
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between transmembrane domains 7 and 8, whereas mouse-derived xCT does
not (Bridges et al., 2001).
4F2hc (also known as CD98) is a type II glycoprotein with a single
transmembrane domain, a molecular weight of ≈ 85-kDa (Jimenez-Vidal et al.,
2004; Palacin and Kanai, 2004). Importantly, the 4F2hc subunit is thought to be
in excess compared to xCT and, as such, need not be dynamically regulated like
its light chain partners (Nakamura et al., 1999; Verrey et al., 2000). 4F2hc is
widely expressed and the tissue and cell-type distribution demonstrate its
importance in a myriad of biological activities. xCT and 4F2hc interact via an
extracellular disulfide bond at residue Cys158 of xCT (Gasol et al., 2004). The
heavy chain of system xc-, 4F2hc, interacts with numerous other amino acid
transporter light chains via a disulfide bridge and functions to traffic the
heterodimer to the plasma membrane (Nakamura et al., 1999). Other roles for
4F2hc have been described such as involvement in cell adhesion/polarity and
functioning as an extracellular signaling molecule (Nguyen et al., 2008; Yan et
al., 2008). In transfected Xenopus oocytes, it has been eloquently demonstrated
that both the light and heavy chains of system xc- are required for transporter
function (i.e. injection of xCT alone or 4F2hc alone cannot produce functional
cystine uptake, whereas co-injection can) (Sato et al., 1999). Similar findings are
observed with human xCT. However, mouse xCT can interact with either heavy
chain 4F2hc or RBAT and have functional transporter activity as assessed by
cystine uptake (Wang et al., 2003), whereas co-expression of human xCT with
human RBAT fails to produce functional transporter activity (Bassi et al., 2001).
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1.3.2 System xc- expression
System xc- is widely distributed in a variety of tissues and is almost
ubiquitously expressed in cultured mammalian cells. xCT mRNA and/or protein is
present in the brain, liver, kidney, stomach, intestines, ovary, spleen, and
numerous other organs and cell types (Lo et al., 2008). Within the CNS, system
xc- is expressed in neurons (Murphy et al., 1990; Burdo et al., 2006; Dun et al.,
2006), astrocytes (Bender et al., 2000; Gochenauer and Robinson, 2001; Pow,
2001; Burdo et al., 2006), microglia (Piani and Fontana, 1994), and glioma cell
lines (Cho and Bannai, 1990; Ye et al., 1999). Further, system xc- is present at
the CNS-periphery interface and highly expressed in vascular endothelial cells,
meningeal cells, and ependymal cells (Burdo et al., 2006) and in situ
hybridization studies show strong expression of xCT mRNA in the area
postrema, subfornical organ, hypothalamus and the meninges (Sato et al., 2002).

1.3.3 System xc- function: Glutathione biosynthesis
In addition to its role in regulating ambient extracellular glutamate, system
xc- has traditionally been studied with respect to its involvement in the
biosynthesis of the antioxidant molecule glutathione (GSH; Figure 1.3). In fact, in
early studies performed by Bannai and Kitamura in IMR-90 cells, approximately
60% of radiolabeled cystine transported into the cells via system xc- is reduced to
cysteine within five minutes, while 15% of imported cystine is rapidly incorporated
into GSH in the same time frame (Bannai and Kitamura, 1980). Thus, the
function of system xc- is intimately related to intracellular glutathione levels.
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Similar findings have demonstrated that enhanced activity of system xcincreases intracellular GSH in an endothelial cell line (MBEC4), a rat retinal
Müller cell line (TR-MUL), and in BHK21 cells derived from the Syrian hamster
kidney (Hosoya et al., 2002; Sasaki et al., 2002; Tomi et al., 2003). Conversely,
in numerous neural cell types, including neurons, gliomas, and oligodendrocyte
precursors, inhibition of cystine transport in with system xc- antagonists such as
glutamate, homocysteic acid, and quisqualate results in diminished intracellular
stores of GSH and subsequent cell death (Murphy et al., 1989; Murphy et al.,
1990; Kato et al., 1992; Oka et al., 1993; Sagara et al., 1993; Ratan et al., 1994;
Back et al., 1998; Chung et al., 2005).
GSH is a peptide composed of glutamate, cysteine, and glycine, and is the
most abundant non-protein thiol in mammalian cells. GSH is best known as a
potent antioxidant molecule that directly detoxifies free radicals, but also serves
as a cofactor for the antioxidant enzyme glutathione peroxidase which
neutralizes hydrogen peroxide and other organic peroxide species. GSH also
plays important roles in cell metabolism and proliferation, gene expression, and
signal transduction (Poot et al., 1995; Dringen, 2000; Wu et al., 2004; Shih et al.,
2006). Glutathione also participates in signal transduction by modifying redoxsensitive proteins in the face of alteration in oxidative and/or nitrosative
homeostasis (Stamler and Hausladen, 1998; Klatt and Lamas, 2000). Hence,
understanding GSH synthesis, metabolism, and regulation is of great import.
Given the inability of GSH to cross the BBB (Cornford et al., 1978), de
novo GSH synthesis within the CNS is essential. The concentration of cysteine in
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the extracellular space is low as its disulfide bond is rapidly oxidized in this
compartment, thus intracellular GSH concentrations are critically dependent on
cystine, the best extracellular precursor for cysteine. Numerous amino acid
transporters

have the ability to import cystine (Kakuda and MacLeod, 1994;

Knickelbein et al., 1997), however, in the CNS, cystine is predominantly
transported via system xc which is the focus of this dissertation (Bender et al.,
2000; Shanker and Aschner, 2001; McBean, 2002).
GSH synthesis occurs in the cytosol via a two-step enzymatic reaction,
catalyzed by γ-glutamylcysteine ligase and glutathione synthetase, with cysteine
as the rate-limiting substrate (Meister and Anderson, 1983; Deneke and Fanburg,
1989; Sagara et al., 1993; Kranich et al., 1996). Once produced glutathione can
be exported from the cell, cleaveg by γ-glutamyltranspeptidase into the γ-glutamyl
moiety and a cysteinylglycine dipeptide, which can be further catabolized via the
action of aminopeptidase N (Dringen et al., 2001).
The concentration of GSH is estimated to range from 1-3 mM in the CNS
and approaches 8 mM in rat astrocyte primary cultures (Dringen and Hamprecht,
1998; Dringen, 2000; Franco et al., 2008). Since astrocytes function as
indispensible support cells for neurons, it may not be surprising that astrocytes
possess higher GSH levels than neurons (Desagher et al., 1996; Wang and
Cynader, 2000), and protect neurons against H2O2, dopamine, and NO-mediated
oxidative insults (Desagher et al., 1996; Tanaka et al., 1999; Chen et al., 2001;
Shih et al., 2003; Jakel et al., 2007). In fact, 10% of astrocytic GSH / hour is
exported to the extracellular compartment (Sagara et al., 1996; Minich et al.,
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2006), with the multidrug resistant protein (Mrp1) transporting approximately 60%
of this GSH released from astrocytes as determined using a competitive Mrp1
inhibitor, MK-571 (Hirrlinger et al., 2002). Importantly, export of GSH and its
extracellular catabolism provides GSH precursors which are utilized for GSH
biosynthesis in neurons. As a result of neuronal dependence on astrocytic GSH,
deficiencies in astrocytic GSH render neurons more susceptible to oxidantinduced injury (Gegg et al., 2005), presumably due to reduced export of GSH
which negatively influences neuronal GSH synthesis (Raps et al., 1989; Sagara
et al., 1993; Kranich et al., 1996; Dringen et al., 1999; Minich et al., 2006; Sun et
al., 2006).
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Figure 1.3.. Schematic of glutathione biosynthesis and metabolism. The
structure of reduced glutathione (GSH) is depicted. Modified from (Owen and
Butterfield, 2010).
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1.3.4 System xc- and disease
The link between system xc- activity and CNS pathology in vivo has been
extensively studied in the context of the biology of gliomas. System xc- is
expressed in rodent and human glioma cell lines and patient-derived gliomas (Ye
et al., 1999; Ye and Sontheimer, 1999; Chung et al., 2005; Lyons et al., 2007;
Ogunrinu and Sontheimer, 2010). Interestingly, the activity of system xcfacilitates tumor growth and expansion within the confines of the skull via
glutamate-mediated excitotoxic neuronal cell death. In fact, glioma cultures can
raise extracellular glutamate concentrations to 500 µM within 12 hr (Ye and
Sontheimer, 1999). This in vitro finding was substantiated in vivo by the finding
that implantation of glioma cells in rats could produce substantial increases in
extracellular glutamate as measured via microdialysis (Behrens et al., 2000).
Further, there is evidence that disruption of system xc- via siRNA-mediated gene
knockdown of xCT reduces glioma-derived glutamate release and reduces
edema and neuronal injury (Savaskan et al., 2008). Additionally, in vitro studies
implicate system xc- activity as contributory to injury in a variety of disease states
including cerebral ischemia (Fogal et al., 2007), Alzheimer’s disease (Barger and
Basile, 2001; Qin et al., 2006), and multiple sclerosis (Domercq et al., 2007).
Further, new in vivo studies note enhanced expression of system xc- following
experimental autoimmune encephalomyelitis (EAE) and speculate a role for
system xc- in demyelinating diseases as oligodendrocytes are also susceptible to
glutamate excitotoxicity (Pampliega et al., 2011).
.
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1.3.5 Animal models deficient in system xc- function
The subtle gray (sut) mouse arose via a natural mutation in the slc7a11
gene which encodes for xCT, the light chain of system xc-. Sut mice possess a
large ≈500,000 base deletion that extends from intron 11 through exon 12 and
into the intergenic region adjacent to the Pcdh18 gene (Chintala et al., 2005). As
a result of this mutation, no xCT protein is produced and the mice have a subtle
coat color phenotype secondary to the inability to create pheomelanin, a
red/yellow pigment produced by the addition of cysteine to dopaquinone
(Chintala et al., 2005). In particular, there is a reduction in the intensity of yellow
pigment in agouti mice such that the coat color is gray, rather than brown with
yellow highlights. In addition to alterations in coat color, these mutant animals
also have prolonged bleeding times which are associated with abnormalities in
platelet dense granules (Swank et al., 1996). Sut mice show evidence of
neurodegeneration that is apparent by 13 weeks of age and is characterized by
ventricular enlargement, striatal atrophy, and cortical thinning (Shih et al., 2006).
In 2005, Sato and colleagues generated an xCT knock-out (KO) mouse
where the xCT gene was disrupted in all cell types via deletion of the translation
initiation site and exon one (Sato et al., 2005). No abnormalities are noted in any
of the organs examined in 8 week old mice including the brain, lung, liver,
pancreas, and kidney. It raises the possibility that the neurodegeneration
observed in sut/sut mice may arise due to the C3H/HeSnJ background, and not
as a function of the loss of xCT gene function. xCT KO mice are viable, fertile,
and healthy in appearance at 6 months. Interestingly, plasma cystine
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concentrations in the xCT KO mice are double the concentrations seen in WT
mice and there are no other differences in amino acid concentrations. The
plasma concentration of GSH in KO mice is half the concentration detected in
WT mice. However, there are no genotype-specific differences in GSH content in
the liver or brain. Remarkably, adaptive compensatory responses must have
been initiated to allow survival of xCT-null animals, because fibroblasts,
melanocytes, and astrocytes derived from xCT mutants [both xCT KO mice and
the spontaneous (sut/sut) mutant mice] fail to thrive in culture in the absence of a
reducing agent such as β-mercaptoethanol (Appendix Figure A1), however,
viability can be rescued with the addition of a reducing agent, such as βmercaptoethanol, in the tissue culture media (Chintala et al., 2005; Sato et al.,
2005; Shih et al., 2006).
Of note, while system xc- is often studied in the context of its contributions
to glutathione synthesis, closer examination of the transporter shows that its role
as a regulator of extracellular glutamate levels is likely more important in vivo as
loss of transporter function dramatic alters extracellular glutamate levels with no
effects of tissue glutathione in the striatum or hippocampus (Massie et al., 2010b;
De Bundel et al., 2011). Irrespective of which biological function is qualitatively
more important, alterations in system xc- activity and/or expression is associated
with pathology thus it is important to understand how this transporter is regulated.
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1.3.6 Regulators of system xc- activity
The activity of system xc- can be dynamically regulated in both positive
and negative fashions. For instance, cellular deprivation of several amino acids
(e.g. cystine, arginine, and tryptophan) or exposure to lipopolysaccharide (LPS),
nitric oxide (NO), dibutyryl cAMP (dBcAMP), or electrophilic reagents such as
diethyl maleate (DEM), increase xCT expression and/or system xc- activity
(Bannai and Kitamura, 1982; Bannai, 1984a; Kim et al., 1987; Miura et al., 1992;
Sato et al., 1999; Bridges et al., 2001; Gochenauer and Robinson, 2001; Kim et
al., 2001; Sato et al., 2001; Nosoya et al., 2002; Tomi et al., 2002; Sato et al.,
2004).
In the CNS, secreted amyloid precursor protein (sAPP), amyloid β-peptide
(Aβ), chronic dBcAMP treatment, and TNF-α, but not IL-1β, can enhance system
xc- activity in microglial cells (Piani and Fontana, 1994; Barger and Basile, 2001;
Qin et al., 2006; Seib et al., in press). Chronic treatment of astrocytes with
dibutyryl cAMP (dBcAMP) enhances the activity of system xc- (Gochenauer and
Robinson, 2001). Previous data from our laboratory indicate that the cytokine IL1β mediates an enhancement of system xc- activity in mixed cortical cell cultures
predominately containing neurons and astrocytes, although cell-type specificity
was not determined in these studies (Fogal et al., 2007).
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1.4.1 Interleukin-1β (IL-1β
β)
IL-1β is a member of the canonical interleukin-1 (IL-1) family that consists
of two agonists IL-1α and IL-1β, an endogenous antagonist IL-1ra, and two
receptors (IL-1RI and IL-1RII). Currently there are 11 known members of the IL-1
family with additional members added to the family based on conservation of key
amino acid sequences and similar three-dimensional structures [reviewed by
(Dinarello, 2009; Sims and Smith, 2010)]. Further discussion will be limited to IL1β, the key cytokine discussed in this thesis. [For a more detailed review of other
IL-1 family members see (Arend et al., 2008; O'Neill, 2008; Sims and Smith,
2010)].
IL-1β is a pleiotropic cytokine with a variety of effects on numerous cell
types. Although IL-1 was the first member of the group of peptides known as
cytokines to be described, it was originally known by more colorful and
functionally descriptive names that demonstrate the role of IL-1β in the
inflammatory

response,

such

as

lymphocyte

activating

factor,

B-cell

differentiation factor, and endogenous pyrogen, among others (Dinarello, 1988).
The last name listed, endogenous pyrogen, highlights the role of IL-1β as a
mediator which influences cells within the immune system but also within the
central nervous system (CNS). Specifically, IL-1β exerts its effects at the level of
hypothalamus to alter body temperature via prostaglandin-mediated induction of
fever [thoroughly reviewed in (Dinarello et al., 1999; Dinarello, 2004)].
The gene encoding IL-1β is located on chromosome 2 in humans and
mice (Webb et al., 1986) and IL-1β is generated as a 31-kDa precursor protein
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referred to as pro-IL-1β. Pro-IL-1β is inactive until cleaved by the intracellular
cysteine protease, caspase-1/ interleukin-1-converting enzyme (ICE), which
produces the mature, functionally active 17-kDa protein (Jobling et al., 1988;
Howard et al., 1991). First, there is a priming step where IL-1β mRNA expression
is enhanced without a concomitant increase in IL-1β protein (Schindler et al.,
1990), whereby various stimuli, such as the complement component C5a,
hypoxia, or adherence of monocytes to glass or plastic surfaces induces large
amounts of IL-1β mRNA without significant translation into protein (Haskill et al.,
1988; Ghezzi et al., 1991; Dinarello, 1998). Without a signal for translation, IL-1β
is rapidly degraded with a half-life ranging from 2 – 4.5 hr (Schindler et al., 1990).
Importantly, mature protein is only detected extracellularly suggesting that the
processing of pro-IL-1β is temporally coordinated with IL-1β release (Hogquist et
al., 1991).
Importantly, the IL-1β precursor protein lacks an N-terminal hydrophobic
signal denoting a cleavage site which would target it for processing by the
endoplasmic reticulum (ER)/Golgi apparatus (Gray et al., 1986) and subsequent
secretion from the cell. In the absence of such a signaling sequence,
immunoelectron

microscopy

utilizing

an

antibody

against human

IL-1β

demonstrates accumulation of the cytokine within the cytoplasm, whereas none
is detected in the ER/Golgi complex or in secretory vesicles of human monocytes
(Singer et al., 1988). Thus, a classical pathway of exocytosis is not utilized for IL1β release.
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Some consensus has been reached in that many agree that IL-1β
secretion is dependent on ATP, its purinergic receptor P2X7 (Sanz and Di
Virgilio, 2000; Solle et al., 2001; Bianco et al., 2005; Clark et al., 2010), and
calcium (MacKenzie et al., 2001; Andrei et al., 2004). Importantly, macrophages
lacking P2X7 receptors fail to secrete IL-1β following ATP exposure, but secretion
induced by the K+ ionophore, nigericin, is not altered in the P2X7-deficient cells
suggesting the involvement of an additional regulatory pathway(s) (Solle et al.,
2001). Additionally, IL-1β is not secreted from lumbar spinal cord slices derived
from P2X7-null mice or in the presence of a P2X7 receptor antagonist (Clark et
al., 2010). There are several schools of thought as to how IL-1β is released
(Figure 1.4). The most parsimonious model of IL-1β release is that it is
transported through uncharacterized transporters located in the plasma
membrane (Brough and Rothwell, 2007). MacKenzie and colleagues propose a
model of release dependent on ATP-induced shedding of IL-1β-containing
microvesicles within seconds of P2X7 receptor activation (MacKenzie et al.,
2001). This is similar to a proposed mechanism where exosome-containing
multivesicular bodies release IL-1β containing exosomes into the extracellular
space (Qu et al., 2007). However, the mechanism by which IL-1β traverses the
microvesicle membrane remains elusive. Qu and colleagues have speculated
that microvesicle membranes, like the plasma membrane, also contain P2X7
receptors which initiate microvesicle lysis in the presence of ATP (Bianco et al.,
2005) or that vesicle lysis is mediated by the action of phospholipases and
proteases from the secretory lysosome (Qu et al., 2007). Notably, Qu and
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colleagues were unable to detect IL-1β-containing microvesicles in the tissue
culture supernatant. Andrei and colleagues present an alternate model where
ATP-mediated

depletion

of

intracellular

K+

activates

caspase-1

and

phophatidylcholine-specific phospholipase C. Ultimately, the activation of
phophatidylcholine-specific phospholipase C and cytosolic phospholipase A2
(cPLA2) trigger lysosome exocytosis and the release of IL-1β, caspase-1, and
other lysosomal enzymes (Andrei et al., 2004). Finally, a novel caspase-1
dependent form of cell death called pyroptosis has been hypothesized to
participate in release of IL-1β via plasma membrane pores under ischemic
conditions and after infection (Bergsbaken et al., 2009). Of note, a study of
diarylsulfonurea-mediated

inhibition

of

cytokine

release

from

human

mononuclear cells (irrespective of the initiating stimuli) demonstrates that
glutathione S-transferase may be involved in the release of IL-1β into the
extracellular space (Laliberte et al., 2003). Further study of the mechanism of
release is warranted, as the full picture remains elusive.
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Figure 1.4. Four models of non-classical IL-1β secretion. Pathway 1
depicts the direct efflux of cytosolic IL-1β (and other inflammasome
components) through uncharacterized transporters. Pathway 2 depicts
microvesicular shedding / blebbing. Pathway 3 depicts Ca2+-dependent
secretory lysosome exocytosis. Pathway 4 depicts the multivesicular
bodies (MVB) / exosome model. Modified from (Qu et al., 2007).
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1.4.2 IL-1 Signaling
Indisputably, IL-1β bind to two receptors, the type I or type II receptor
referred to as IL-1RI or IL1-RII, respectively (Sims et al., 1988). Both the IL-1RI
and IL1-RII receptors are located on chromosome 2 in humans and chromosome
1 in mice (Mantovani et al., 1998). These two receptors are similar in that both
receptors possess three extracellular immunoglobin-like domains, however the
cytosolic domains differ greatly.

IL-1RI possesses an ≈ 200 amino acid

intracellular domain whereas the intracellular domain of IL-1RII consists of ≈ 29
amino acids (Dinarello, 1991). As one might expect, receptor function varies as a
consequence of the structural differences in the cytosolic domain. A long
intracellular domain allows IL1-RI to signal (Sims et al., 1993), whereas the
absence of a signaling domain in IL1-RII renders it a “decoy receptor”, thought to
serve as a negative regulator (McMahan et al., 1991; Colotta et al., 1994).
IL-1RI signaling culminates in the activation of several signaling pathways
including the nuclear factor-κB (NF-κB) pathway,

the p38 mitogen activated

protein (MAP) kinase pathway, and the c-Jun N-terminal kinase (JNK) pathway
(for a more detailed review see (O'Neill and Greene, 1998; Ichijo, 1999; Dunne
and O'Neill, 2003)). Since IL-1β preferentially activates NF-κB in astrocytes
(Srinivasan et al., 2004), the classical activation of NF-κB will be the only
pathway discussed and is as follows: IL-1β binds to IL-1RI which induces a
conformational change in IL-1RI (Vigers et al., 1997) facilitating the interaction
with its accessory protein, IL-1RAcP (Greenfeder et al., 1995). The interaction
between IL-1RI and the accessory protein recruits the adaptor protein myeloid
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differentiation primary response gene 88 (MyD88) (Lord et al., 1990) to the TollIL-1 receptor (TIR) domain of the IL-1RI/IL1RAcP complex, and deletion of this
domain causes a loss of IL-1 signaling/ functional activity (Heguy et al., 1991;
Brikos et al., 2007). The N-terminal death domain of MyD88 then interacts with
IL-1R-associated kinases (IRAKs) which become phosphorylated and activate
tumor necrosis factor receptor associated factor 6 (TRAF6). TRAF6 then
activates the inhibitor of NF-κB kinase (IKK), which phosphorylates the inhibitor
of NF-κB (IκB) which is ubiquitinated and degraded by the proteasome allowing
p65 and p50 (NF-κB) to enter the nucleus. Signaling is terminated via
internalization of the signaling receptor complex and the activation of negative
regulators such as Toll-interacting protein (Tollip) which interacts with IRAK1 and
is believed to facilitate termination of IL-1RI signaling

[For a more detailed

review see (Carroll et al., 2005; Brissoni et al., 2006; Weber et al., 2010)].
The IL-1 system is tightly regulated and inhibition of IL-1β-mediated
signaling can be accomplished via IL-1ra occupation of the IL-1β binding site on
IL-1RI. Importantly, the endogenous antagonist IL-1ra cannot induce the
conformational change in IL-1RI required to promote an interaction with the
accessory protein IL-1RAcP (Greenfeder et al., 1995). Additionally, the decoy
receptor IL1-RII competes with IL1-RI for IL-1β binding (Colotta et al., 1993; Re
et al., 1994). IL-1RII can interact with the accessory protein, IL-1AcP which would
interfere with the normal IL-1RI / IL-1AcP complex formation (Lang et al., 1998;
Wang et al., 2010). Finally, both IL1-RI and IL-1RII can be shed from the
membrane to sequester ligands (Penton-Rol et al., 1999; Orlando et al., 2000)
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Of note, there are three studies that propose the existence of an additional
IL-1 responsive signaling receptor in the CNS that remains to be conclusively
identified (Parker et al., 2002; Touzani et al., 2002; Andre et al., 2006). Touzani
and colleagues demonstrate that IL-1β enhances injury in IL-1RI-null mice
following middle cerebral artery occlusion (MCAO) and that injury is not
attenuated by the concomitant administration of IL-1β and its endogenous
antagonist IL-1ra (Touzani et al., 2002). Furthermore, Andre and colleagues
found that IL-1β increases the expression of approximately 400 genes in mixed
glial cultures derived from IL-1RI-null mice compared to vehicle treated mixed
glial cultures (that have alterations in the expression of almost 1300 genes in
response to IL-1β) (Andre et al., 2006). Importantly, contaminants such as
endotoxin in the recombinant IL-1β preparation could produce identical results in
an IL-1RI-independent manner, however this possibility was not discussed.

1.4.3 IL-1β and CNS physiology
IL-1β has important functions within a normal, but immunologically
challenged organism, and its role in the regulation of temperature and sickness
behavior, and in the initiation of the inflammatory response has been extensively
studied and will not be discussed here [for a detailed review see (Dinarello, 2004;
Dantzer and Kelley, 2007)]. Since cytokines function as intercellular messages,
additional functions of IL-1β outside the traditional realm of inflammation have
been reported. IL-1β induces changes that may protect neurons and promote
growth and/or survival via stimulated production of neurotrophic factors,
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chemokines and cytokines, and their receptors including GRO-α, tumor necrosis
factor (TNF-α), IL-6, and the growth factors nerve growth factor (NGF), ciliary
neurotrophic factor (CNTF), vascular endothelial growth factor (VEGF), fibroblast
growth factor 2 (FGF-2), hepatocyte growth factor (HGF), and granulocyte
colony-stimulating factor (G-CSF) (Gadient et al., 1990; Albrecht et al., 2002;
Meeuwsen et al., 2003; John et al., 2005).
Long-term potentiation is defined as a “form of synaptic plasticity which is
characterized by a persistent increase in synaptic efficacy following tetanic
stimulation of an afferent pathway. On the basis of its properties, LTP has been
proposed as a biological substrate for learning and memory” (Lynch, 1998).
Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR)
demonstrates that IL-1β expression is enhanced one hour after LTP induction in
rat hippocampal slices, and similar findings are observed in vivo in the ipsalateral
hippocampus of rats that had robust potentiation lasting at least 8 hr (Schneider
et al., 1998). IL-1RI knockout mice have deficits in hippocampal dependent
spatial learning suggesting that endogenous IL-1β may promote LTP and
learning (Avital et al., 2003) This is particularly interesting in light of the finding
that TNFα, a cytokine induced by IL-1β, promotes astrocytic glutamate release
by regulating the number of readily releasable glutamatergic vesicles adjacent to
the plasma membrane (Santello et al., 2011) Others have found that IL-1ra has
no effect on the induction of LTP, whereas administration of IL-1ra after LTP
induction impairs the maintenance phase (Schneider et al., 1998; Coogan et al.,
1999). Additionally, lipopolysaccharide (LPS), a potent inducer of IL-1β
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expression, can produce learning and memory deficits (Tanaka et al., 2006).
While LPS-treatment was associated with an increase in IL-1β as assessed via
immunohistochemistry, it remains to be ascertained whether this phenomenon is
IL-1β-dependent. which have been hypothesized to occur via inhibition of Ca2+
currents in hippocampal neurons (Plata-Salaman and Ffrench-Mullen, 1992,
1994), or via the enhancement of GABA currents (Miller et al., 1991). In sum,
endogenously produced IL-1β appears necessary for the expression and
maintenance of LTP in hippocampal slices (Schneider et al., 1998; Avital et al.,
2003). In contrast, higher concentrations of IL-1β applied exogenously or induced
via LPS, which mimic pathological IL-1β expression, inhibit LTP (Bellinger et al.,
1993; Cunningham et al., 1996; Murray and Lynch, 1998; Coogan et al., 1999;
Avital et al., 2003; Ross et al., 2003).

1.4.4 IL-1β and CNS disease
There is a place for IL-1β in normal physiology, however, dramatic
deviations from low levels of basal expression are thought to underlie the ability
of IL-1β to facilitate injury. IL-1β is dramatically upregulated in a variety of acute
and chronic neurological diseases and disorders [for a thorough review see
(Allan et al., 2005; Gosselin and Rivest, 2007; Fogal and Hewett, 2008)]. The
strongest evidence for the participation of IL-1β in neuronal injury in a disease
state stems from experimental ischemia models. Like numerous other
neurological diseases and disorders, IL-1β mRNA and protein are increased after
transient and permanent middle cerebral artery occlusion (MCAO) in rodents
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(Minami et al., 1992; Liu et al., 1993; Buttini et al., 1994; Sairanen et al., 1997;
Davies et al., 1999; Pearson et al., 1999). Yamasaki demonstrated that
intraventricular injection of IL-1β enhances neuronal injury in rats following
MCAO (Yamasaki et al., 1995). In contrast, intracerebroventricular administration
and genetic overexpression of IL-1ra, the endogenous antagonist, before MCAO,
is protective and reduces infarct size (Relton and Rothwell, 1992; Betz et al.,
1995; Loddick and Rothwell, 1996; Yang et al., 1997; Mulcahy et al., 2003).
Finally, animals lacking both IL-1α and IL-1β (but not either ligand alone) (Boutin
et al., 2001; Ohtaki et al., 2003), the signaling receptor IL-1RI (Basu et al., 2005;
Fogal et al., 2007), or ICE/capase-1, the enzyme required for IL-1β processing
(Hara et al., 1997a; Hara et al., 1997b; Schielke et al., 1998; Liu et al., 1999), are
protected against hypoxic/ischemic injury. Additionally, administration of an IL-1β
neutralizing antibody improves outcomes following ischemia in rats (Yamasaki et
al., 1995).
From a clinical research perspective, IL-1β levels in humans increase
following cerebral ischemia in a manner consistent with findings from
experimental studies. The concentration of IL-1β measured in the CSF of stroke
patients is increased 2 days post stroke, which then declines over time to control
values, with no observable alterations in plasma IL-1β concentration (Griffin et
al., 1994; Tarkowski et al., 1995). Impressively, clinical trials have demonstrated
that intravenous administration of recombinant human IL-1ra can penetrate the
blood brain barrier (BBB) following stroke and improve clinical outcomes three
months post-stroke (Emsley et al., 2005).
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Our laboratory is interested in understanding the mechanism by which IL1β contributes to neuronal injury following cerebral ischemia. As such, we have
developed an in vitro model of the metabolically active, yet functionally impaired
tissue surrounding the ischemic core, which is referred to as the ischemic
penumbra. Using in vitro cortical preparations we have devised a model that
recapitulates the injury that is observed in the ischemic prenumbra. Notably,
treatment of cultures with exogenous IL-1β, to mimic release from microglia and
deprivation of oxygen leads to a potentiation of neuronal cell death (Fogal et al.,
2005a; Fogal et al., 2007). Injury can be blocked with the endogenous
antagonist, IL-1ra or a IL-1β blocking antibody. Injury is dependent on glutamatemediated excitotoxicity, astrocytes, and extracellular cystine. As such, we
identified system xc- as a target of IL-1β whereby inhibition of this transporter
attenuates injury (Fogal et al., 2007).
While the deleterious role of IL-1β in ischemia is clear, similar to the
dichotomy observed with system xc-, enhanced levels of IL-1β need not
contribute to injury in all disorders. In fact, elevations in IL-1β expression may
function to promote tissue repair. Mice lacking IL-1β show reduced remyelination
in a cuprizone model of demyelination, with the inability to properly remyelinate
occurring secondary to a reduction in insulin-like growth factor-1 (IGF-1) (Mason
et al., 2001). Further support of the beneficial role of IL-1β comes from the finding
that chronic overexpression of IL-1β reduces pathology in a mouse model of AD
(Shaftel et al., 2007). Interestingly, mice deficient in IL-1RI had less neuronal
sprouting and functional recovery after 6-hydroxydopamine-mediated injury to the
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substantia nigra pars compacta, compared to their wild-type counterparts (Parish
et al., 2002). Importantly, in vitro findings further support the assertion that IL-1β
can promote positive outcomes by reducing excitotoxic neuronal cell death
induced by the ionotropic glutamate receptor agonists NMDA, AMPA, and
kainate (Strijbos and Rothwell, 1995; Ohtsuki et al., 1996; Wang et al., 2000;
Pringle et al., 2001; Bernardino et al., 2005).

1.5

Significance
A variety of neurological diseases and disorders are associated with

excitotoxicity, oxidative stress, and enhanced expression of IL-1β (Fogal and
Hewett, 2008) and system xc- unites all these components. Although system xc- is
best known for its role in the synthesis of the antioxidant molecule GSH
(Watanabe and Bannai, 1987; Bannai et al., 1989; Miura et al., 1992; Sato et al.,
1995a; Bridges et al., 2001; Dun et al., 2006; Lewerenz et al., 2009a), enhanced
transporter activity and subsequent efflux of glutamate in the CNS has been
demonstrated to contribute to neuronal and oligodendrocyte injury both in vitro
and in vivo (Barger and Basile, 2001; Chung et al., 2005; Qin et al., 2006;
Domercq et al., 2007; Fogal et al., 2007; Savaskan et al., 2008; Sontheimer,
2008). Hence, the activity of system xc- must be tightly controlled. However, it is
plausible that enhanced activity of the transporter may arise as a protective
mechanism to limit oxidative stress – and excitotoxicity is the unfortunate
consequence of a protective response gone awry. Understanding the regulation

38

of system xc- will be required to devise therapies to increase system xc- and
intracellular GSH to reduce oxidative injury, and when appropriate, to employ
strategies to reduce its activity to decrease the probability of excitotoxic neuronal
injury.
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1.6

Specific Aims
Because enhanced activity of system xc- can facilitate excitotoxic injury or

promote the synthesis of the antioxidant glutathione depending on the context, it
is important to understand how the transporter is regulated. Our laboratory has
demonstrated that the cytokine interleukin-1β (IL-1β) ─ which is upregulated in
numerous neurological diseases/disorders ─ enhances the activity of the amino
acid transporter system xc-, mediating an increase in extracellular glutamate and
in cellular cyst(e)ine, a constituent of the tripeptide antioxidant molecule
glutathione (GSH). Thus, the objective of this dissertation was to elucidate the
cellular, molecular, and biochemical mechanisms by which IL-1β regulates
system xc-. Further, the functional consequences of system xc- activity under
pathophysiological and physiological conditions were evaluated.

1.6.1 Specific Aim #1: To determine the cell type(s) responsible for enhanced
system xc- activity in response to IL-1β.
The Hewett laboratory previously demonstrated that interleukin-1β (IL-1β)
increases system xc- (cystine/glutamate antiporter) activity in mixed cortical cell
cultures containing neurons and astrocytes in a manner dependent on astrocyte
IL-1RI activation (Fogal et al., 2007), yet the specific cell type(s) responding to IL1β via an enhancement in system xc- activity was not ascertained. Thus the goal
of this specific aim was to identify which specific cell type(s) responds to IL-1β by
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enhancing the expression and functional activity of system xc- by exposing
purified populations of neurons, astrocytes, and microglia to IL-1β (Chapter 2).

1.6.2 Specific Aim #2: To elucidate the consequences of system xc- activity
under pathological (Chapter 3) and physiological (Chapter 4) conditions.
The Hewett lab previously demonstrated that IL-1β potentiates hypoxic
and hypoglycemic neuronal injury (Fogal et al., 2005a). The IL-1β-mediated
enhancement in system xc- activity in mixed cortical cell cultures resulted in a
potentiation of hypoxic neuronal injury when glutamate clearance was impaired
(Fogal et al., 2007). Despite longstanding evidence that hypoglycemic neuronal
injury is also mediated by glutamate excitotoxicity, the role of system xc- in this
paradigm had not been assessed. Specifically, mixed cortical cell cultures were
deprived of glucose for up to 8 hr and pharmacological and genetic techniques
were employed to assess the involvement of system xc- in hypoglycemia-induced
neuronal injury.
Additionally, the enhancement in system xc- activity by IL-1β under
physiological (normoxic and normoglycemic) conditions was assessed by treating
astrocytes with IL-1β and measuring intracellular and extracellular glutathione
levels. Other cellular proteins participating in GSH biosynthesis, export, and
metabolism in response to IL-1β were also evaluated to see if IL-1β alters their
expression. Finally, we assessed if the IL-1β-mediated enhancement of system
xc- activity could confer protection against an oxidative stressor.
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CHAPTER 2

Regulation of system xc- activity and expression in astrocytes by
interleukin-1β
β: implications for hypoxic neuronal injury

This chapter is a near duplicate of the previously published work:

Jackman N. A., Uliasz T. F., Hewett J. A. and Hewett S. J. (2010) Regulation of
system xc- activity and expression in astrocytes by interleukin-1β: implications for
hypoxic neuronal injury. Glia 58, 1806-1815.
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2.1

Summary
We recently demonstrated that interleukin-1β (IL-1β) increases system xc-

(cystine/glutamate antiporter) activity in mixed cortical cell cultures, resulting in
an increase in hypoxic neuronal injury when glutamate clearance is impaired.
Herein, we demonstrate that neurons, astrocytes and microglia all express
system xc- subunits (xCT, 4F2hc, RBAT) and are capable of cystine import.
However, IL-1β stimulation increases mRNA for xCT ─ the light chain that
confers substrate specificity ─ in astrocytes only; an effect blocked by the
transcriptional inhibitor actinomycin D. Additionally, only astrocytes show an
increase in cystine uptake following IL-1β exposure; an effect associated with a
change in xCT protein. The increase in cystine uptake that follows IL-1β is
lacking in astrocytes derived from mice harboring a mutation in Slc7a11 (sut
gene), which encodes for xCT, and in wild-type astrocytes treated with the
protein synthesis inhibitor cycloheximide. IL-1β does not regulate the light chain
of the amino acid transporter, LAT2, or the expression and function of astrocytic
excitatory amino acid transporters (EAATs), demonstrating some target
selectivity. Finally, the enhanced neuronal vulnerability to hypoxia that followed
IL-1β treatment in our mixed culture system was not observed in chimeric
cultures consisting of wild-type neurons plated on top of sut astrocytes. Nor was
it observed in wild-type cultures treated with a system xc- inhibitor or an NMDA
receptor antagonist. Overall, our data demonstrate that IL-1β selectively
regulates system xc- activity in astrocytes and that this change is specifically
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responsible for the deleterious, excitotoxic effects of IL-1β found under hypoxic
conditions.

2.2

Introduction
System xc- is a heteromeric amino acid transporter consisting of two

subunits: xCT ─ the light chain that confers substrate specificity ─ and a heavy
chain (4F2hc or RBAT) thought to target the transporter to the plasma membrane
(Sato et al., 1999; Bassi et al., 2001). The import of cystine via system xc- is
directly coupled to glutamate export, occurring in a Na+-independent, Cl-dependent manner with 1:1 stoichiometry (Bannai, 1986; Reichelt et al., 1997).
Although, system xc- is best known for its role in the synthesis of the antioxidant
molecule glutathione (GSH) (Watanabe and Bannai, 1987; Bannai et al., 1989;
Miura et al., 1992; Sato et al., 1995a; Bridges et al., 2001; Dun et al., 2006;
Lewerenz et al., 2009a), enhanced transporter activity has been reported to
contribute to neuronal and oligodendrocyte injury both in vitro and in vivo (Barger
and Basile, 2001; Chung et al., 2005; Qin et al., 2006; Domercq et al., 2007;
Fogal et al., 2007; Savaskan et al., 2008; Sontheimer, 2008).
System xc- subunits and activity have been demonstrated to be
dynamically regulated. For instance, xCT expression and/or the activity of system
xc- is enhanced following deprivation of certain cellular amino acids or exposure
to lipopolysaccharide (LPS), nitric oxide (NO), dibutyryl cAMP (dBcAMP), or to
electrophilic reagents such as diethyl maleate (DEM) (Miura et al., 1992; Bridges
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et al., 2001; Gochenauer and Robinson, 2001; Sato et al., 2004). Recently, we
demonstrated that the cytokine, IL-1β, enhances system xc- activity (i.e.
increases Vmax) in a mixed cortical cell culture system (Fogal et al., 2007). While
increased activity is not toxic alone, presumably because system XAG- (glutamate
transport) is sufficient to prevent the toxic accumulation of extracellular glutamate
− under conditions where glutamate uptake is compromised (i.e., hypoxia), this
IL-1β-mediated

enhancement

of

system

xc-

activity

contributed

to

an

enhancement of extracellular glutamate levels, which resulted in excitotoxic
neuronal cell death (Fogal et al., 2005a; Fogal et al., 2007). Although we
previously determined that this enhancement in hypoxic neuronal injury in mixed
cortical cell culture was dependent on astrocyte IL-1RI signaling, the cell type
that demonstrated an increase in transporter activity was not ascertained (Fogal
et al., 2007). As our cultures contain predominantly neurons and astrocytes with
some contaminating microglia, the cellular and molecular target of system xcenhancement by IL-1β was examined herein using purified populations of
primary astrocyte, neuron, and microglial cultures. Results indicate that IL-1β
regulates the expression and activity of system xc- in astrocytes exclusively and
that glutamate released via astrocytic system xc- directly underlies the neurotoxic
propensity of IL-1β under hypoxic conditions.
Part of the work has been published in abstract form (Jackman et al., 2009;
Jackman and Hewett, 2009).
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2.3

Materials and Methods

2.3.1 Cell culture
Cell culture media and experimental buffer compositions were as follows:
Media stock (MS): L-glutamine-free modified Eagle’s medium (Earl’s salt;
MediaTech) supplemented with L-glutamine, glucose, and sodium bicarbonate to
a final concentration of 2.0, 25.7, and 28.2 mM, respectively; Glial plating media:
MS containing 10% fetal bovine serum (FBS; Hyclone) and 10% calf serum (CS;
Hyclone), 10 ng/ml epidermal growth factor (Invitrogen), 50 IU penicillin, and 50
µg/ml streptomycin (Gibco/BRL); Neuronal plating media: Neurobasal media
containing 1x B27 (Invitrogen), 2 mM L-glutamine, 50 IU penicillin and 50 µg/ml
streptomycin; Mixed culture plating media: MS containing 5% CS, 5% bovine
growth serum (BGS, Hyclone), 50 IU penicillin, and 50 µg/ml streptomycin.
Microglia growth media: DMEM (high glucose; Gibco) containing 5% FBS, 2mM
L-glutamine, 50 IU penicillin, 50 µg/ml streptomycin and 50% LADMAC (ATCC) conditioned media to supply colony stimulating factor-1 (Sklar et al., 1985). To
produce LADMAC conditioned media, the LADMAC cell line (CRL-2420, ATCC,)
was grown to confluence in DMEM containing 5% FBS, 2 mM L-glutamine, 50 IU
penicillin and 50 µg/ml streptomycin in 75 cm2 flasks for ~14 days followed by
harvesting, centrifugation (720 x g; 3 min) and filtering of the culture supernatant,
which is then stored at -80°C. Maintenance media: MS containing 10% CS and
50 IU penicillin/ 50 µg/ml streptomycin; HBSS (mM): 120 NaCl, 5.4 KCl, 0.8
MgCl2, 1.8 CaCl2, 15 glucose, 20 HEPES, 10 NaOH, and 0.01 glycine (pH 7.4).
Balanced Salt Solution [BSS (mM)]: 116 NaCl, 5.4 KCl, 0.8 MgCl2, 1 NaH2PO4,
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26.2 NaHCO3, 1.8 CaCl2, 0.01 glycine, 2 L-glutamine, 1x MEM amino acids
(Invitrogen), and 5 or 20 mM glucose (BSS5 or BSS20, respectively).
Primary astrocyte cultures were derived from pooled cortices of day 1-3
postnatal CD1 mouse pups (Charles River Laboratories) or from mouse pups
derived from sut heterozygous breeding pairs (JAX; Stock # 001310) or sut
control mice (C3H/HeSnJ; JAX; Stock # 000661) essentially as described
(Trackey et al., 2001). Additionally, wild-type (WT) and sut (xCT-deficient)
astrocytes were cultured from cortices of single pups derived from sut/+ breeding
pairs (JAX; Stock # 001310). β-mercaptoethanol (β-ME; 55 µM) was added to the
glial plating medium of sut cultures to support growth and to WT cultures for
control purposes (Shih et al., 2006). The rest of the brain was used for
genotyping: WT primers (230 bp product) 5’- GAA GTG CTC CGT GAA GAA GG
3’ (forward), 5’- ATC TCA ATC CTG GGC AGA TG-3’ (reverse); sut primers
(≈2280 bp product) 5’-CCA CTG TTG TAG GTC AGC TTA GG-3’ (forward), 5’CAG GAC CTG TGA ATA TGA TAG GG 3’ (reverse). Il1r1 wild-type and null
mutant astrocytes were cultured from cerebral cortices of single pups derived
from Il1r1 heterozygous breeding pairs (JAX; stock # 003245). Following
dissection of the cerebral cortices, the rest of the brain was used for genotyping
as described [http://jaxmice.jax.org/strain/003245.html]. Cells from cerebral
cortices were dissociated, plated (Falcon Primaria; BD Biosciences) and once
confluent, then treated with 8 µM β-D-arabinofuranoside (AraC; Sigma) once for
4-7 days to reduce the number of microglia. Purified astrocyte cultures were
generated by removing residual microglia by treatment with 75 mM L-leucine
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methyl ester for 60-90 min, one day prior to experimentation (Hamby et al.,
2006a). Cultures were ≤ 35 days in vitro at the time of experimentation. Microglia
cultures were prepared by plating dissociated cortical cells from CD1 mouse
pups (1-3 days) in T25 tissue culture flasks (2 hemisphere/5 ml/flask) in glial
plating medium. Fourteen to 21 days later, the culture medium was
supplemented with HEPES buffer to a final concentration of 25 mM and flasks
shaken overnight at 150 rpm (37°C). The supernatant containing dislodged
microglia was collected, spun (3 min; 720 x g) and the resulting pellet
resuspended in microglial growth media and plated in 15 mm 24-well plates
(Corning) (Hamby et al., 2006b). Primary neuronal cultures were derived from
dissociated cortical cells of embryonic day 15 CD1 mouse fetuses using a
modification of the protocol of Brewer and colleagues (Brewer et al., 1993). Two
days after plating in neuronal plating medium, cultures were treated once with 1
µM AraC for two days, then media was partially replenished (½ volume
exchange) twice weekly. Experiments were performed on pure neuronal cultures
after 7-10 days in vitro. Mixed cortical cell cultures containing predominantly
neurons and astrocytes with a small amount of contaminating microglia were
prepared by isolating cortices obtained from embryonic day 15 mouse fetuses
and plating them on a confluent layer of astrocytes in mixed culture plating media
(Trackey et al., 2001). After 7 days in vitro, mixed cultures were treated with 8 µM
AraC for 2 days then switched into maintenance media. The media was changed
after 5 and 9 days in vitro, and one day prior to experimentation, cells were
placed into MS. Experiments were performed on mixed cortical cultures after 13-
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14 days in vitro. All cultures were maintained at 37°C in a humidified 6% CO2containing atmosphere.

2.3.2 IL-1β
β Treatment
Cells were treated with 3 ng/ml recombinant murine IL-1β (R&D Systems)
for various times in an incubation buffer of MS (neurons and astrocytes) or
microglial growth media (microglia) both supplemented with 0.1% fatty-acid free
BSA (Sigma). Cells were then returned to a humidified 37˚C normoxic (21% O2)
incubator containing 6% CO2.

2.3.3 Radiolabeled L-cystine and D-aspartate uptake
System xc- specific

14

C-L-cystine (PerkinElmer) and system XAG--mediated

3

H-D-aspartate (PerkinElmer) uptake was performed as previously described

(Fogal et al., 2007). Cultures were washed into HBSS (3 x 750 µL) and allowed
to equilibrate for 10 min (25˚C). For cystine uptake, cells were incubated in HBSS
containing 3 µM

14

C-L-cystine (1 µCi/ml), 27 µM unlabeled cystine, 1mM D-

aspartate and 0.5 mM acivicin (Biomol). D-aspartate and acivicin were included
in the uptake buffer to block system XAG- and γ-glutamyltranspeptidase,
respectively. Uptake was terminated by washing in ice-cold PBS (3 x 750 µL).
For D-aspartate uptake, cells were incubated in HBSS containing 0.1 µCi/ml 3HD-aspartate and varying concentrations of unlabeled D-aspartate (25˚C) for 5 min
and uptake terminated by washing cells with an ice-cold Na+-free choline stop
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buffer containing in mM: 116 choline chloride, 0.8 MgSO4, 1 KH2PO4, 10 HEPES,
5 KOH, 10 glucose, 0.9 CaCl2, and 5 non-radioactive D-aspartate. Varying
concentrations of unlabeled D-aspartate were used to span the Km of the
different astrocytic glutamate transporters (Danbolt, 2001), ensuring that the
concentration of non-radioactive D-aspartate used was not rate-limiting. Cells
were lysed with warm 0.5% SDS and accumulated radioactivity estimated using
a liquid scintillation counter. Uptake was normalized to total protein as
determined by the BCA Assay (Pierce).

2.3.4 Reverse transcriptase-PCR analysis
Three or four wells of cells grown in 24 well tissue culture plates were
combined, the RNA was extracted (TRIzol, Invitrogen) and then suspended in 20
µL RNase-free water. First-strand cDNA was synthesized from 0.5-1µg RNA
using M-MLV reverse transcriptase (400 U, Invitrogen) and oligo (d)T primers
(Promega) as previously described (Hewett et al., 1999). Reactions were
performed in 20 µL volumes at 40-42°C for 1 hr. Each RNA sample was
incubated similarly in the absence of reverse transcriptase to test for genomic
DNA contamination (none detected). PCR amplimer pairs for analysis of specific
cDNAs are as follows:
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Amplimers

Annealing Temp.

xCT

5′-AAACTTGCTAAGCTCTGTGTTGG-3′
5′-CACATCACATGTTTGTACACTCG-3′

(sense)
(antisense)

63 ˚C

4F2hc

5'-GCCCAATTCACAAGAACCAG-3'
5'-CCTAGTGACTAGGGATTCAG-3'

(sense)
(antisense)

60 ˚C

RBAT

5’-TTGCCATTTATCCAGGAAGC-3’
5’-AGTTTGTGGGTAGCCAGGTG-3’

(sense)
(antisense)

60 ˚C

β-actin

5’-GTGGGCCGCTCTAGGCACCAA-3’
5’-CTCTTTGATGTCACGCACGATTTC-3’

(sense)
(antisense)

63 ˚C

Table 2.1- PCR amplimer pairs for RT-PCR.

PCR was performed on 1 µL of cDNA using Taq DNA polymerase (1 U,
Invitrogen) in a total volume of 25 µL. Each cycle consisted of a denaturation
step (94 °C; 30 sec), an annealing step (45 sec), and a primer extension step (72
°C, 1 min). PCR products were separated by electrophoresis in 2% agarose with
1 kb size markers (Invitrogen) and visualized by ethidium bromide (BioRad) using
a UV transilluminator.

2.3.5 Quantitative Real-time PCR (qPCR)
RNA was isolated and first-strand cDNA synthesized as described above.
qPCR was performed using mouse-specific primer pairs [Taqman Gene
Expression Assays, Applied Biosystems: xCT (Mm00442530_m1); 4F2hc
(Mm00500521_m1); RBAT (Mm00486218_m1); EAAT-1 (Mm00600697_m1);
EAAT-2 (Mm00441457_m1); LAT2 (Mm00444250_m1)] per manufacturer’s
instructions. Reactions were run in the Applied Biosystems Fast Real-Time PCR
System and relative quantification performed using the comparative cycle
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threshold method (∆∆CT), where CT values of the transcript of interest were
normalized to β-actin CT values from the same sample, then compared to a
calibrator CT value (untreated cells) to determine the relative fold increase in
mRNA. β-actin CT values were unaffected by IL-1β treatment. Statistics were
performed on the logarithmic retransformation (i.e. geometric means) of 2-∆∆CT
values. Preliminary experiments were performed to establish that the
amplification efficiency for each of the primer pairs was >94%.

2.3.6 Immunoblotting
Protein expression was determined by Western Blot analysis. Astrocytes
in 24-well plates were washed twice with ice-cold PBS then incubated in 50 µL
lysis buffer [50 mM Tris, pH 8.0, 1.0% Nonidet-P40 (NP40), 150 mM NaCl, and
protease inhibitor cocktail (Roche)] for 30 minutes on ice. Cells were harvested
by scraping, lysates from eight wells pooled, cellular debris removed by
centrifugation (10,000 x g; 15 min; 4°C), and the resulting supernatants stored at
-20°C. After thawing, proteins were concentrated via ethanol precipitation. The
pelleted protein was resuspended in 1x urea buffer (50 mM Tris, pH 6.8, 2.5%
glycerol, 5% SDS, 4 M Urea, 10 mM DTT, 0.02% bromophenol blue). One
hundred µg protein (BCA assay; Pierce) was separated by 10% SDS-PAGE
under reducing conditions and electrophoretically transferred to a nitrocellulose
membrane (0.2 µm; Bio-Rad). Proteins of interest were detected sequentially
using species-specific Western Breeze Immunodetection kits (Invitrogen) per
manufacturer’s instructions. Primary antibodies and incubation times were as
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follows: xCT (2 µg/ml; rabbit polyclonal; Novus Biologicals; 2 h at 37° C), β-actin
(0.3 µg/ml; mouse monoclonal; Sigma; 2 h at 37° C) or CD98 (4F2hc; 0.4 µg/ml;
goat polyclonal; Santa Cruz; overnight at 4° C). Results were recorded on X-ray
film

(FujiFilm).

Digitized

images

were

analyzed

by

computer-assisted

densitometry (Gel-Pro Analyzer) and xCT and 4F2hc protein normalized to their
respective β-actin levels.

2.3.7 Hypoxia
Mixed cortical cell cultures were placed into an anaerobic chamber
(Thermolabs) containing a gas mixture of 5% CO2, 10% H2, and 85% N2 (<0.2%
O2). Culture medium was replaced by thorough exchange with a deoxygenated
balanced salt solution (BSS5). Cells were placed in a 37°C incubator within the
chamber for 4-5 hr and then returned to a 37°C, 6% CO2-containing normoxic
(21% O2) incubator. Parallel cultures within the same plate were placed into
deoxygenated BSS20 to assess for neuronal injury unrelated to the experimental
paradigm. Importantly, in the presence of 20 mM glucose, cells can resist
neuronal injury for nearly 12 hr of oxygen deprivation (Fogal et al., 2005b).
Neuronal cell death was assessed 20-24 hr later.

2.3.8 Measurement of neuronal cell death
Neuronal cell death was quantitatively determined by measurement of
lactate dehydrogenase (LDH) released into the culture supernatant as described
previously (Uliasz and Hewett, 2000). Data are expressed as a percentage of
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total neuronal LDH activity (defined as 100%), determined by assaying the
supernatant of parallel cultures exposed to 200 µM NMDA for 20-24 hr. Since
primary cortical astrocytes do not contain NMDA receptors (Backus et al., 1989;
Chan et al., 1990; Janssens and Lesage, 2001) nor have been shown by us to
be injured by oxygen deprivation times up to 12 hr (Fogal et al., 2005a), changes
in LDH activity can be used as a specific marker of neuronal injury in this system.

2.3.9 Statistical Analysis
All statistical analyses were performed using GraphPad Prism (Version
4.03, GraphPad Software, Inc.) as described in each figure legend. Percentage
data were first transformed via arcsin square root. For qPCR, statistics were
∆∆CT

performed on the logarithmic retransformation (i.e. geometric means) of 2-

values. In all experiments, data are expressed as the mean ± SEM. Significance
was assessed at p < 0.05.

2.4

Results
We previously demonstrated in a mixed cortical cell culture system that IL-

1β potentiated neuronal injury induced by hypoxia (Fogal et al., 2005a) via a
process dependent on increased system xc- activity and impaired glutamate
clearance (Fogal et al., 2007). Although, it was determined that this increase
required astrocyte IL-1 receptor I (IL-1RI) signaling, the specific cell type(s)
responding was not ascertained (Fogal et al., 2007). Hence, initial experiments
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utilized purified cell culture preparations of neurons, astrocytes, and microglia to
identify which cell types express xCT ─ the system xc- light chain ─and 4F2hc
and RBAT ─the system xc- heavy chains ─ demonstrate functional cystine
uptake, and respond to IL-1β by increasing system xc- activity.
Under basal conditions, xCT, 4F2hc, and RBAT transcripts are present in
mixed cortical cell cultures and in each of the purified populations of cells:
astrocytes, neurons, and microglia (Figure 2.1). Further, all culture preparations
functionally express system xc- as determined by their ability to import
radiolabeled cystine (Figure 2.2A-C; white bars). However, only astrocytes
respond to IL-1β treatment (3 ng/ml; 20-24 hr) with an enhancement in cystine
uptake (Figure 2.2A; black bars). No change in uptake was observed in pure
neuronal or microglial cultures following IL-1β exposure at any time point
assessed (Figure 2.2B,C).
Since IL-1β is known to regulate the expression of various genes, we next
assessed whether its treatment (3 ng/ml) alters xCT steady-state mRNA
expression in purified astrocyte, neuronal, and microglial cultures using
quantitative PCR. Consistent with the uptake data, IL-1β elicits a time-dependent
increase in xCT mRNA in astrocyte (Figure 2.3A), but not neuron or microglial
cultures (Figure 2.3B), such that a 4-8 hr incubation produces ≈12-fold increase
in astrocytic xCT mRNA (Figure 2.3A). Transcripts for the system xc- heavy
chains do not increase following IL-1β stimulation (Figure 2.3C).
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The increase in astrocytic steady-state xCT mRNA that follows IL-1β
treatment (3 ng/ml; 6 hr) is not observed in astrocytes derived from IL-1RI -/mice (Figure 2.4A). Further, simultaneous exposure of pure astrocytes with IL-1β
(3 ng/ml; 6 hr) and the transcriptional inhibitor actinomycin D (10 µg/ml; 6 hr)
blocks the IL-1β-mediated increase in xCT mRNA expression; basal levels
remain unchanged (Figure 2.4B). Consistent with the qPCR data, IL-1β treatment
enhances protein levels of astrocyte xCT (Figure 2.5A,B), whereas 4F2hc levels
are unaffected (Figure 2.5A,C). Finally, concomitant exposure of astrocytes to IL1β (3 ng/ml) and actinomycin D (12.5 µg/ml; 24 hr), prevents the IL-1β-mediated
enhancement in cystine uptake, as does incubation with the protein synthesis
inhibitor cycloheximide (1 µg/ml; 24 hr) (Figure 2.6).
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Figure 2.1. Cellular system xc- expression. (A) Total RNA was isolated
from unstimulated mixed cortical cell cultures (mix; lanes 1
1-2), pure
astrocytes (lanes 3-5),
5), pure neurons (lanes 6
6-8),
8), and pure microglia (lanes
9-11),
11), reverse transcribed, and PCR performed using specific primers for
xCT (33 cycles),
cles), 4F2hc (33 cycles), RBAT (33 cycles) and β-actin
β
(23
cycles) in separate reactions
reactions.

57

ASTROCYTES

A

- IL-1β
β

*

[

+IL-1β
β

150

[

*

100

*

[

50

14

C-CYSTINE UPTAKE
(pmol / mg protein)

200

0
5

B

10

15

30

60

30

60

30

60

NEURONS
100

50

14

C-CYSTINE UPTAKE
(pmol / mg protein)

150

0
5

C

10

15

MICROGLIA
800
600
400
200

14

C-CYSTINE UPTAKE
(pmol / mg protein)

1000

0
5

10

15

TIME (min)

Figure 2.2. Astrocytes increase cystine uptake following IL-1β
β
treatment. Astrocytes (A; n=4), neurons (B; n=4-8) and microglia (C;
n=6-10) were treated with vehicle (white bars) or IL-1β (3 ng/ml; black
bars) for 20-24 hr following which cells were washed and incubated with
a buffer containing 14C-L-cystine (3 µM) and uptake was determined over
time as indicated. Data are expressed as mean ± SEM 14C-L-cystine
uptake in pmol/ mg protein. An asterisk (*) indicates a significant
between-group difference as determined by a two-way ANOVA followed
by Bonferroni’s post hoc test. Significance was set at p < 0.05.
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Figure 2.3. IL-1β
β selectively increases astrocytic xCT mRNA. (A) Pure
astrocytes (n=4) (B) neurons (n=4) and (inset) microglia (n=4) were treated
with IL-1β (3ng/ml) or its vehicle for the indicated durations and xCT mRNA
assessed via qPCR. Data are expressed as mean ± SEM fold change in
xCT mRNA compared to untreated cells (0 h) (C) Astrocytes (n=3) were
treated with IL-1β (3ng/ml) or its vehicle for the indicated durations and
4F2hc and RBAT (inset) mRNA expression was assessed via qPCR. Data
are expressed as mean ± SEM fold change in 4F2hc and RBAT mRNA
compared to untreated cells (0 h). An asterisk (*) denotes values different
from 0 hr as assessed by one-way ANOVA. Significance was set at p < 0.05.
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Figure 2.4. IL-1R1 signaling and transcription are required for the
enhancement in astrocyte xCT mRNA expression. (A) Astrocytes (n=4-5)
were treated with IL-1β (3 ng/ml) or its vehicle for 6 h. Thereafter, total RNA
was isolated, reverse transcribed and xCT and β-actin expression assessed
using quantitative PCR. Data are expressed as mean ± SEM fold change in
xCT mRNA compared to Il1r1 +/+ untreated cells (-IL-1β). (B) Astrocytes (n=
5) were treated with IL-1β (3 ng/ml) or its vehicle in the presence and
absence of actinomycin D (Act D; 10 µg/ml) and xCT mRNA expression
assessed via qPCR 6 hr later. Data are expressed as mean ± SEM fold
change in xCT mRNA compared to untreated cells (-IL-1β, -Act D). An
asterisk (*) denotes values different from control and a pound sign (#)
indicates values that significantly differ from IL-1β-treated conditions as
assessed by two-way ANOVA followed by Bonferroni’s post hoc test.
Significance was set at p <0.05.
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Figure 2.5. IL-1β
β increases xCT protein expression. (A) Pure astrocyte
cultures were incubated with vehicle or 3 ng/ml IL-1β in the absence or
presence of cycloheximide (CHX 1 µg/ml) for 20-24 hr. Protein from
unstimulated C6 glioma cells was used as a positive control for xCT protein.
Lane 1, Basal; Lane 2, IL-1β; Lane 3, IL-1β+CHX, Lane 4, C6 positive
control. Representative of two western blots. (B,C) Films were scanned and
densitometry performed using Gelpro Analyzer software. (B) xCT and (C)
4F2hc protein levels were normalized to their corresponding β-actin protein
levels and expressed as a fold increase (mean ± SEM; n = 2) over control
(basal; set to 1).
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We next set out to ascertain whether the astrocytic excitatory amino acid
transporters (EAATs / system XAG-) are coordinately regulated by IL-1β, since
glutamate efflux via system xc- is balanced by system XAG--mediated glutamate
uptake (Danbolt, 2001; McBean, 2002). Treatment of astrocytes with IL-1β (3
ng/ml) does not enhance EAAT-1 (aka GLAST) or EAAT-2 (aka GLT-1) mRNA
expression (Figure 2.7A) in the same time frame as it does xCT (Figure 2.3A).
Additionally, there is no difference in astrocytic 3H-D-aspartate uptake−used here
as a measure of EAAT activity− following a 24 hr exposure to IL-1β as compared
to control (Figure 2.7B). Finally, the mRNA expression of LAT-2, a light chain of
the System L amino acid transporter, is also unchanged by IL-1β stimulation
(Figure 2.7A), further demonstrating target specificity of the IL-1β response. To
elucidate the functional importance of these findings and definitively test whether
astrocyte-mediated

alterations

in

system

xc-

activity

contribute

to

the

development and progression of inflammatory (IL-1β-enhanced) hypoxic
neuronal injury, astrocytes derived from sut mice − which carry a functional
mutation in xCT (Chintala et al., 2005) − were utilized. Since no PCR genotyping
protocol currently exists to detect the truncated slc7a11 (sut) gene, astrocytes
were derived from the pooled cortices of the progeny obtained from
heterozygous breeders (sut/+).
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Figure 2.6. Protein synthesis is required for the enhancement of
astrocyte system xc- activity that follows IL-1β
β treatment. Pure
astrocyte cultures (n =11-12) were treated with actinomycin D (ACT D; 12.5
µg/ml) or cycloheximide (CHX; 1 µg/ml) in the absence (white bars) or
presence (black bars) of IL-1β (3 ng/ml) for 20-24 hr following which 14C-Lcystine uptake (3 µM labeled + 27µM unlabeled; 25˚C) was determined.
Data are expressed as mean ± SEM 14C-L-cystine uptake in pmol/30
min/mg protein. An asterisk (*) denotes values different from control (-IL1β) and a pound sign (#) indicates values different from IL-1β-treated
conditions as assessed by two-way ANOVA followed by Bonferroni’s post
hoc test. Significance was set at p < 0.05.
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Figure 2.7. IL-1β
β does not regulate mRNA expression or activity of
system XAG amino acid transporters. (A) Pure astrocyte cultures (n= 3-4)
were treated with IL-1β (3ng/ml) or its vehicle for the indicated durations and
EAAT-1, EAAT-2, and LAT2 mRNA expression assessed via qPCR. Data
are expressed as mean ± SEM fold change in mRNA compared to untreated
cells (0 h). (B) Pure astrocyte cultures (n =10) were treated with vehicle
(white bars) or IL-1β (3 ng/ml; black bars) for 20-24 hr following which 3H-Daspartate (0.1 µCi/ml labeled + 1-100 µM unlabeled; 25˚C) uptake was
determined. Data are expressed as mean ± SEM 3H-D-aspartate uptake in
cpm x 103/5 min/mg protein. No significant between-group differences were
found via two-way ANOVA.
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According to Mendelian inheritance (¼ +/+, ½ sut/+, ¼ sut/sut), cultures
should have ≈50% reduction in functional sut gene expression. Indeed,
astrocytes derived from sut animals demonstrate 61 ± 6% less cystine uptake
compared to WT astrocytes when cultured under basal conditions (Figure 2.8A).
Moreover, sut astrocytes do not respond to IL-1β with an increase in cystine
uptake as do cultures derived from wild-type controls (Figure 2.8A). Finally, the
enhanced neuronal vulnerability to hypoxia that follows IL-1β treatment in our
mixed culture system (Fogal et al., 2007) −which is recapitulated herein (Figure
2.8B, 2.9)− is not observed in chimeric cultures consisting of wild-type neurons
plated on top of sut astrocytes (Figure 2.8B, Appendix Figure A2). Nor is it
observed in wild-type cultures treated with a system xc- inhibitor (50 µM
LY367385) or an NMDA receptor antagonist (10 µM MK-801) (Figure 2.9), as
was similarly demonstrated by us previously (Fogal et al., 2007). Together, these
data demonstrate that IL-1β selectively regulates system xc- activity in astrocytes
and that this change is specifically responsible for the deleterious, excitotoxic
effects of IL-1β found under hypoxic conditions.
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Figure 2.8. Cystine uptake and hypoxic neuronal cell death are reduced
in cultures containing sut astrocytes. (A) Pure astrocyte cultures (n = 5-6)
derived from either wild-type (white bars) or sut mice (black bars) [all cultured
w/ 55 µM β-ME] were treated with vehicle or IL-1β (3 ng/ml) for 20-24 hr after
which 14C-L-cystine uptake was determined. Data are expressed as mean ±
SEM 14C-L -cystine uptake in pmol/30 min/mg protein. (B) Chimeric mixed
cortical cell cultures were obtained by plating WT neurons on astrocytes
derived from sut mice (black bars). These and control cultures (WT neurons on
WT astrocytes; white bars) were treated with 1 ng/ml IL-1β or vehicle for 20-24
hr, washed, and then deprived of oxygen for 5 hr. The percentage of total
neuronal cell death was determined 20-24 hr later (n = 4 cultures pooled from
two independent experiments). An asterisk (*) indicates a significant withingroup difference, while a pound (#) sign indicates a significant between-group
difference as determined by a two-way ANOVA followed by Bonferroni’s post
hoc test. Significance was set at p < 0.05.
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Figure 2.9. Ionotropic glutamate receptor and system xc- antagonism
prevent IL-1β-mediated hypoxic neuronal injury. Mixed cortical cell
cultures were treated with 3 ng/ml IL-1β for 20-24 hr, washed, and then
deprived of oxygen for 4 hr. The ionotropic glutamate receptor antagonist MK801 (10 µM) and the system xc- antagonist LY367385 (50 µM) were added at
the initiation of hypoxia. The percentage of total neuronal cell death was
determined 20-24 hr later (n = 5-6 cultures pooled from 2 independent
experiments). An asterisk (*) denotes values different from control untreated
cultures (hypoxia) and a pound sign (#) indicates values different from IL-1βtreated conditions as assessed by one-way ANOVA followed by a StudentNewman-Keul’s post hoc test. Significance was set at p < 0.05.

67

2.5

Discussion
Several studies have demonstrated that system xc- is an important

contributor to the ambient extracellular glutamate levels that bathe the central
nervous system (Jabaudon et al., 1999; Warr et al., 1999; Baker et al., 2002a;
Baker et al., 2002c; Melendez et al., 2005; Augustin et al., 2007; Featherstone
and Shippy, 2008). Additionally, system xc- activity has been demonstrated to
control synapse strength and courtship behavior in drosophila (Grosjean et al.,
2008), as well as, drug seeking and sensitization behavior in rodents (Baker et
al., 2002a; Moran et al., 2005; Baker et al., 2008). Finally, its activity can also
contribute to neuropathology. For instance, export of glutamate via system xcproduces an excitotoxic necrosis that aids in glioma tumor growth, migration, and
invasion (Ye et al., 1999; Ye and Sontheimer, 1999; Lyons et al., 2007;
Savaskan et al., 2008; Sontheimer, 2008). Further, the deleterious effect of Aβ-,
secreted β-amyloid precursor protein (sAPP)- or LPS-treated microglia or IL-1βtreated mixed cultures on neuronal and oligodendrocyte survival in vitro has been
shown to be caused by system xc- -mediated excitotoxicity (Piani and Fontana,
1994; Barger and Basile, 2001; Qin et al., 2006; Domercq et al., 2007; Fogal et
al., 2007). Thus, understanding the regulation of system xc- at the cellular and
molecular level is of great import. Toward this end, the central observation of this
study is that IL-1β enhances the functional expression of system xc- in astrocytes
specifically and selectively via a process dependent on IL-1R1 signaling and de
novo protein synthesis. Of pathological relevance, this IL-1β-mediated increase
in astrocytic system xc- activity enhances neuronal injury initiated by hypoxia.
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Demonstration of the expression of xCT, 4F2hc and RBAT mRNA in
purified populations of neurons, astrocytes and microglia indicate that each cell
type has the molecular machinery necessary for the formation of a functional
system xc- antiporter (Figure 2.1). That these transcripts are translated to
functional protein is demonstrated by the ability of each cell type to take up
cystine in a system xc- -dependent manner (Figure 2.2). While others have
demonstrated xCT mRNA expression in neurons (Dun et al., 2006; Ogawa et al.,
2008) and retinal Muller cells (Tomi et al., 2003; Mysona et al., 2009), this is the
first report of xCT mRNA expression in astrocytes and microglia, although xCT
protein expression has been demonstrated in all three cell types (Burdo et al.,
2006; Dun et al., 2006; Domercq et al., 2007; La Bella et al., 2007). Previous
studies have also demonstrated functional system xc- activity in neurons (Murphy
et al., 1990; Dun et al., 2006), astrocytes (Cho and Bannai, 1990; Bender et al.,
2000; Pow, 2001; Tang and Kalivas, 2003; Lewerenz et al., 2009a), and
microglia (Piani and Fontana, 1994; Barger and Basile, 2001; Nakamura et al.,
2003; Barger et al., 2007; Domercq et al., 2007).
Interestingly, of the three cell types studied, only astrocytes respond to IL1β by increasing the mRNA of the system xc- light chain xCT − though not the
heavy chains (Figure 2.3A,C) − and by increasing cystine uptake (Figure 2.2A).
Additionally, IL-1β induces expression of xCT protein in astrocytes (Figure 2.5).
As increases in mRNA do not always translate to similar changes in protein
expression, it is not surprising that ≈12-fold increase in xCT mRNA expression
(Figures 2.3, 2.4) only resulted in an approximate four-fold change in xCT protein
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expression (Figure 2.5). Additionally, the discrepancy between changes in
protein levels (4 fold) and the increase in cystine uptake (2 fold) (Figures 2.6)
may occur as a function of the experimental system utilized to specifically isolate
cystine transport via system xc-. The presence of 1mM D-aspartate −used to
inhibit XAG--mediated cystine uptake − is known to alter the driving force required
for optimal system xc- activity (Reichelt et al., 1997).
Conclusive demonstration that the IL-1β-mediated enhancement in cystine
uptake is mediated by astrocytic system xc- comes from our observation that
astrocytes derived from sut animals (Swank et al., 1996; Chintala et al., 2005) fail
to demonstrate this effect (Figure 2.8A). Both of these results are consistent with
several studies, in neural and non-neural systems, which demonstrate an
association between xCT mRNA expression and system xc- activity (Bridges et
al., 2001; Sato et al., 2001; Tomi et al., 2003; Sato et al., 2004; Dun et al., 2006;
Mysona et al., 2009). The lack of coordinate regulation of the subunits might not
be too surprising as the heavy chains are utilized by other transport systems and
as such exist in cells in excess (Stevens and Vo, 1998; Verrey et al., 2004). It
should be noted, however, that there is at least one study that describes a
parallel increase in xCT and 4F2hc mRNA occurring in response to LPS (Sato et
al., 2001).
The fact that microglia system xc- components (Figure 2.3B) and activity
(Figure 2.2C) are unaffected by treatment with IL-1β is consistent with other
studies utilizing cells of the macrophage/monocyte lineage (Piani and Fontana,
1994; Sato et al., 1995a). This finding may be due to the fact that microglia have
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a low ratio of signaling (i.e. IL-1RI) to decoy (i.e. IL-1RII) receptors making them
relatively unresponsive to IL-1β (Pinteaux et al., 2002). Whether this same
mechanism accounts for the inability of IL-1β to alter system xc- in neurons
remains to be determined. Additionally, it is possible that the differential signaling
that follows IL-1RI activation in neurons and astrocytes (Srinivasan et al., 2004)
fosters xCT regulation in one cell type and not the other.
The IL-1β-mediated increase in steady-state xCT mRNA is due, at least in
part, to the initiation of transcription following IL-1RI activation (Figure 2.4).
Whether the latter occurs via activation of transcription factors known to facilitate
transcription of the xCT promoter in response to amino acid deprivation, LPS,
and oxidative stress (e.g., Nrf2 and ATF4) (Sasaki et al., 2002; Sato et al., 2004;
Lewerenz et al., 2009a) remains to be determined. The failure of IL-1β to
increase xCT protein expression (Figure 2.5) and cystine uptake (Figure 2.6) in
the presence of cycloheximide suggests that de novo synthesis and subsequent
insertion of a functional transporter into the membrane are required.
Cycloheximide also prevented the enhancement of transporter activity mediated
by LPS in mouse microglia (Piani and Fontana, 1994), by glucose/glucose
oxidase (i.e. oxidative stress) in human endothelial cells (Miura et al., 1992), and
by an NO donor in retinal pigment epithelial cells (Bridges et al., 2001).
Nevertheless, the requirement of transcription and translation may be cell,
species, and/or stimulus-specific (Barger et al., 2007). Additionally, posttranscriptional regulation of system xc- components and activity in astrocytes in
response to the antibiotic ceftriaxone has recently been described (Lewerenz et
71

al., 2009a).
Not only does IL-1β demonstrate cellular specificity, but it appears to show
target specificity as well. IL-1β had no effect on the expression of the system L
transporter light chain, LAT2, or the expression and function of astrocytic
excitatory amino acid transporters, EAAT-1 and EAAT-2 (Figure 2.7). System L,
and LAT-2 in particular, was chosen as a potential target as it is expressed in
brain (Segawa et al., 1999), it mediates the uptake of the neutral amino acids
cysteine and methionine (Oxender et al., 1977; Sato et al., 1987; Segawa et al.,
1999), and because methionine can be converted in the brain to cysteine via
transulfuration, a process linked to GSH biosynthesis/homeostasis (Vitvitsky et
al., 2006). EAATs were assessed as it is possible that glutamate import
machinery could be cooperatively regulated to maintain low extracellular
glutamate levels. The lack of effect on the EAATs may not be surprising
considering the abundance at which they are expressed in astrocytes (Bergles
and Jahr, 1997; Lehre and Danbolt, 1998). Additionally, this agrees with previous
studies that note no alterations in system XAG- function in the face of increased
system xc- activity (Lewerenz et al., 2009a; Mysona et al., 2009).
The data described herein coupled with our previous studies (Fogal et al.,
2005a; Fogal et al., 2007) suggest the following scenario (Figure 2.10). As
System xc- is an obligate exchanger, the import of cystine is coupled to glutamate
export. Under physiological conditions, the accumulation of glutamate is
prevented by its rapid clearance from the extracellular space via system XAG-.
Consequently, no neuronal toxicity is observed ─ demonstrating that increased
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activity of system xc- is not inherently injurious (Fogal et al., 2005a). In contrast,
when glutamate uptake is impaired, increased system xc- activity can result in the
accumulation of extracellular glutamate and subsequent excitotoxic neuronal cell
death (Fogal et al., 2007). This work advances our previous study by
demonstrating unequivocally that IL-1β enhances system xc- activity in astrocytes
exclusively (Figure 2.2) and that this increase is responsible for the potentiation
of neuronal injury found under hypoxic conditions. To wit, sut astrocytes ─ with
impaired functional system xc- ─ neither increase cystine uptake in response to
IL-1β (Figure 2.8A) nor support the ability of IL-1β to mediate hypoxic neuronal
injury when co-cultured with neurons (Figure 2.8B).
In summary, we have analyzed expression of xCT mRNA and the activity
of system xc- in purified astrocyte, neuron, and microglial cultures in the presence
and absence of IL-1β, a cytokine known to be upregulated in and to contribute to
various neurological disorders [for review see (Fogal and Hewett, 2008)]. The
results unequivocally demonstrate that astrocytes increase system xc- expression
and activity in response to IL-1β, whereas neurons and microglia do not. The
enhancement in astrocytic transporter activity requires transcription and
translation, demonstrates specificity for the xCT subunit, and is responsible for
the increase in hypoxic inflammatory (IL-1β-mediated) neuronal cell death.
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Figure 2.10. Schematic of the system xc- amino acid transporter under
normoxic and hypoxic conditions. The import of cystine via system xc- is
directly coupled to glutamate export, occurring in a Na+-independent,
independent, Cl-dependent manner with 1:1 stoichiometry. XAG- transports glutamate into the
cell to maintain the driving force for system xc- (Reichelt et al., 1997) (left
panel). Under hypoxic conditions, enhanced export of glutamate via system
xc- in combination with reduced glutamate clearance by system XAGproduces an accumulation of extracellular glutamate which contributes to
excitotoxic neuronal cell death (right panel). [Based on results described
herein as well as those found in Fogal et a
al., 2005, 2007)].
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CHAPTER 3

Non-cell autonomous influence of astrocyte system xc- on
hypoglycemic neuronal cell death
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3.1

Summary
Despite longstanding evidence that hypoglycemic neuronal injury is

mediated by glutamate excitotoxicity, the cellular and molecular mechanisms
involved remain incompletely defined. Here, we demonstrate that the excitotoxic
neuronal injury that follows glucose deprivation is mediated by glutamate
extruded from astrocytes via system xc- ─ an amino acid transporter that imports
L-cystine and exports L-glutamate. Specifically, we find that depriving mixed
cortical cell cultures of glucose for up to 8 hr results in increased extracellular
glutamate [glutamate]e levels that injure neurons, but not astrocytes. Neuronal
injury is prevented by ionotropic glutamate receptor antagonism but is insensitive
to tetanus toxin. Removal of amino acids during the deprivation period prevents
— whereas addition of L-cystine restores — the enhancement of [glutamate]e
and neuronal injury, implicating the cystine/glutamate antiporter, system xc-.
Drugs known to inhibit system xc- also suppress glucose deprivation-induced
enhancement of [glutamate]e and neuronal injury. Further, a dramatic reduction
in neuronal injury is observed in chimeric cultures consisting of neurons derived
from wild-type mice plated on top of astrocytes derived from sut mice, which
harbors a naturally occurring null mutation in the gene (Slc7a11) which encodes
the substrate specific light chain of system xc- (xCT). Finally, enhancement of
astrocytic system xc- expression and function via exposure to IL-1β potentiates
hypoglycemic neuronal injury, the process of which is prevented by removal of Lcystine and/or addition of system xc- inhibitors. Thus — under the conditions of
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glucose deprivation — our studies demonstrate that astrocytes, via system xc- ,
have a direct, non–cell autonomous effect on cortical neuron survival.

3.2

Introduction
Hypoglycemia is a medical emergency that arises as a serious

complication of insulin therapy in diabetic patients. It is also prevalent in
neonates, in patients with insulin-producing tumors, and can occur as a
consequence of brain ischemia. Severe hypoglycemia, defined as less than 2
mM blood glucose, essentially renders the brain aglycemic, leading to cognitive
impairments and frank neuronal injury (Ryan et al., 1990; Langan et al., 1991).
Evidence indicates that hypoglycemic/aglycemic neuronal cell death is mediated
by glutamate excitotoxicity (Wieloch, 1985; Monyer et al., 1989). Following
activation of glutamate receptors, a cascade of biochemical events is initiated
that ultimately leads to neuronal cell death via processes dependent on reactive
oxygen species, neuronal zinc release, activation of poly(ADP-Ribose)
polymerase-1 (PARP), and alterations in mitochondrial function. Inhibition of
these downstream targets of glutamate receptor activation show some success
in reducing hypoglycemic brain injury [for review see (Suh et al., 2007)].
However, the cellular and molecular mechanisms surrounding glutamate
release/accumulation remain incompletely defined.
System xc- is a heteromeric amino acid transporter consisting of two
subunits: xCT ─ the light chain conferring substrate specificity ─ and a heavy
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chain thought to target the transporter to the plasma membrane (Sato et al.,
1999; Bassi et al., 2001). The import of cystine via system xc- is directly coupled
to glutamate export, which occurs in a Na+-independent manner (Bannai and
Kitamura, 1980). Enhanced system xc- activity has been previously reported to
contribute to excitotoxic neuronal injury in numerous experimental paradigms
(Piani and Fontana, 1994; Ye et al., 1999; Barger and Basile, 2001; Qin et al.,
2006; Fogal et al., 2007; Savaskan et al., 2008; Sontheimer, 2008; Jackman et
al., 2010; Massie et al., 2010a). Herein, we describe astrocytic system xc- as the
source of glutamate required for the initiation of non-cell autonomous neuronal
injury following glucose deprivation in vitro.

3.3

Materials and Methods

3.3.1 Cell culture
All media including media stock (MS), glial plating medium, mixed culture
plating medium, maintenance medium, and glucose-free balanced salt solution
(BSS) have been fully described (see Chapter 2.3.1). For most experiments,
BSS0 contains purchased 1x MEM amino acids (Invitrogen). Amino acids were
reconstituted individually for the removal and addition experiments.
Primary astrocyte cultures were derived from cerebral cortices of day 1-3
postnatal CD1 mouse pups (Charles River) as described (Trackey et al., 2001;
Jackman et al., 2010). Wild-type (WT) and sut (xCT-deficient) astrocytes were
cultured from cortices of single pups derived from sut/+ breeding pairs (JAX;
Stock # 001310). β-mercaptoethanol (β-ME; 55 µM) was added to the glial
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plating medium of sut cultures to support growth and to WT cultures for control
purposes (Shih et al., 2006). The rest of the brain was used for genotyping: WT
primers (230 bp product) 5’- GAA GTG CTC CGT GAA GAA GG 3’ (forward), 5’ATC TCA ATC CTG GGC AGA TG-3’ (reverse); sut primers (≈2280 bp product)
5’-CCA CTG TTG TAG GTC AGC TTA GG-3’ (forward), 5’-CAG GAC CTG TGA
ATA TGA TAG GG 3’ (reverse).
Mixed cortical cell cultures containing predominantly neurons and astrocytes
were prepared by culturing dissociated cells from embryonic day 15 mouse
fetuses onto a confluent layer of astrocytes in mixed culture plating media as
previously described (Trackey et al., 2001; Jackman et al., 2010). Experiments
were performed on mixed cortical cultures after 13-14 days in vitro.

3.3.2 Glucose Deprivation
Mixed cortical cell cultures were washed thoroughly (8 x 750 µL) into
BSS0. Glucose (final concentration=10mM) was immediately added to parallel
cultures to serve as controls and added back to experimental conditions to
terminate glucose deprivation at the times indicated in each figure legend.
Inhibitors — with the exception of an overnight incubation with tetanus toxin —
were given at the initiation of glucose deprivation.

3.3.3 Glutamate Uptake
System

XAG--mediated

3

H-D-aspartate

(PerkinElmer)

uptake

was

performed as previously described (Fogal et al., 2007; see Chapter 2.3.3) using
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0.1 µCi/ml 3H-D-aspartate and 50 µM unlabeled D-aspartate (5 min; 25˚C).
Accumulated radioactivity was estimated using a liquid scintillation counter and
values normalized to protein [BCA Assay (Pierce)].

3.3.4 Measurement of cell death
Cell

death

was

quantitatively

determined

by

spectrophotometric

measurement of lactate dehydrogenase (LDH) as described previously (Uliasz
and Hewett, 2000). Data are expressed as a percentage of total neuronal LDH
activity (defined as 100%) determined by exposing parallel cultures to 250 µM
NMDA (20-24 hr). Since primary cortical astrocytes neither express NMDA
receptors nor are injured by glucose deprivation up to 8 hr (Figure 3.1 inset),
changes in LDH activity can be used as a specific marker of neuronal injury. In
general, basal LDH released from control cultures was subtracted from values
obtained in experimental conditions to yield the signal specific to hypoglycemic
injury. Astrocyte injury was quantified as a percentage of total astrocytic LDH
activity (defined as 100%) determined by exposure of parallel cultures to 5 µM
Calphostin C for 20-24 hr (Ikemoto et al., 1995).

3.3.5 Measurement of glutamate
Samples of the bathing media from the mixed cortical cultures were stored
at -80°C until analyzed. Two hundred microliters were assayed for glutamate via
HPLC by an investigator blinded to the treatment conditions as described (Fogal
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et al., 2007). Glutamate levels were calculated by normalizing to glutamate
standards which were linear over the range of 0.1–100 µM.

3.3.6 IL-1β
β Treatment
To selectively enhance astrocytic system xc- expression/activity (Jackman
et al., 2010), cultures were treated with 0.01-1 ng/ml recombinant murine IL-1β
(R&D Systems) in an incubation buffer of MS supplemented with 0.1% fatty-acid
free BSA (Sigma).

3.3.7 Quantitative Real-time PCR (qPCR)
Quantitative PCR was performed using mouse-specific primer pairs
[Taqman

Gene

Expression

Assays,

Applied

Biosystems:

xCT

(Mm00442530_m1)] per manufacturer’s instructions using the comparative cycle
threshold method (∆∆CT) with β-actin as the housekeeping control as described
(Jackman et al., 2010). β-actin CT values were unaffected by IL-1β treatment.
Amplification efficiency was >94%.

3.3.8 Statistical Analysis
Statistical analyses were performed using GraphPad Prism Software
(Version 4.03) as described in each figure legend. Percentage data were first
transformed via arcsin square root. For qPCR, statistics were performed on the
logarithmic retransformation (i.e. geometric means) of 2-∆∆CT values. In all
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experiments, data are expressed as the mean ± SEM. Significance was
assessed at p < 0.05.

3.4

Results
Following glucose deprivation, there is a time-dependent increase in

neuronal injury in the mixed cortical cultures (Figure 3.1A), whereas purified
astrocytes (Figure 3.1 inset) and astrocytes in mixed cultures are resistant for up
to 8 hr, the longest time-point assessed. Neuronal injury is associated with
accumulation of glutamate in the tissue culture supernatant (Figure 3.1B) and is
prevented by ionotropic glutamate receptor antagonism (Figure 3.1C). Overnight
incubation with 300 ng/ml tetanus toxin — a concentration which cleaves
neuronal synaptobrevin-2 (data not shown) and blocks depolarization-induced
glutamate release in our system (Taylor and Hewett, 2002; Fogal et al., 2005b)
— failed to attenuate neuronal damage (Figure 3.1D). Alterations in classical
glutamate re-uptake transporter function also did not appear to contribute to the
observed accumulation of [glutamate]e as 3H-D-aspartate uptake under control
conditions and following 6 h of glucose deprivation in astrocytes (Figure 3.2A)
and in mixed cultures (Figure 3.2B) did not differ statistically. Notably, in mixed
cultures with concentrations of cold D-aspartate that span the Km’s of all
glutamate

transporters,

no

difference

in

uptake

was

observed

under

hypoglycemic conditions (Figure 3.2B). Further, glucose deprivation did not alter
system xc- activity as assessed via the uptake of radiolabeled cystine (Figure
3.3).
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Both neuronal injury and glutamate accumulation resulting from glucose
deprivation was, however, inhibited by 4-CPG or LY367385 (each at 50 µM) but
not YM298198 (10 µM) (Figure 3.4). The former are drugs that inhibit both
system xc- and mGluR1α, whereas the latter is a selective mGluR1α antagonist
(Fogal et al., 2007). Complete removal of amino acids during the deprivation
period prevented — whereas addition of L-cystine alone restored — the
enhanced [glutamate]e and hypoglycemic neuronal injury, further supporting a
role for system xc- (Figure 3.5A,C). Likewise, the solitary removal of L-cystine
during the glucose deprivation period prevented hypoglycemic neuronal cell
death. Removal and/or addition of L-methionine had no effect (Figure 3.5 A-C),
attesting to the requirement of L-cystine.
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Figure 3.1. Non-synaptically released glutamate contributes to
hypoglycemic neuronal injury. Mixed cortical cultures or astrocytes (inset) were
incubated in media containing (hatched bars) or lacking (black bars) glucose. The
percentage of total cell death (A) and glutamate accumulation in the tissue culture
supernatant (B) were determined at the times indicated. Between group
differences (*) were determined by one-way (astrocytes) or two-way ANOVA
(mixed cultures) followed by Bonferroni’s post hoc test (n=11-12 cultures from four
different experiments). (C) Mixed cortical cultures were washed into BSS0
containing vehicle, MK-801 (10 µM), or MK-801 plus CNQX (30 µM) for 8 hr (GD).
Neuronal injury was determined 20-24 hr later. (*) indicates values significantly
different from control conditions (10.56 ± 3.02%); (#) represents a significant
diminution of GD-induced injury [one-way ANOVA followed by Student-NewmanKeul’s post hoc test. (n=11 cultures from three separate experiments)]. (D) Mixed
cultures were incubated overnight with vehicle or tetanus toxin (TeNT; 300 ng/ml),
then washed into BSS0. Eight hr later, glucose (10 mM) was added and the
cultures were placed back into the incubator, after which neuronal injury was
assessed (20-24 hr). (*) indicates values significantly different from control
conditions (5.71 ± 2.03%) [one-way ANOVA followed by Student-Newman-Keul’s
post hoc test]. No between-group differences exist (n = 8-9 cultures from three
separate experiments).
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Figure 3.2 Hypoglycemia does not impair glutamate uptake in
astrocytes or mixed cultures. (A) Pure astrocytes (n=10 culture wells
from 2 independent experiments) were incubated in media containing
(hatched bars) or lacking (black bars) glucose for 1-6 hr after which 3H-Daspartate (0.1 µCi/ml labeled + 50 µM unlabeled; 25˚C) uptake was
determined in the presence and absence of the competitive, nontransportable EAAT inhibitor TBOA (500 µM). (B) Mixed cortical cultures (n
=6 from 2 independent experiments) were incubated in media containing
(hatched bars) or lacking (black bars) glucose. for 6 hr after which 3H-Daspartate (0.1 µCi/ml labeled + 1-100 µM unlabeled; 25˚C) uptake was
determined. Data are expressed as mean ± SEM 3H-D-aspartate uptake in
cpm /5 min/mg protein. No significant between-group differences were
found via two-way ANOVA.
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Figure 3.3. Hypoglycemia does not increase the activity of system xc- .
Mixed cortical cultures (n =6) were deprived of glucose for 0-8 hr after which
they were incubated in a buffer containing 14C-L-cystine (3 µM; 25˚C) and
uptake was determined over 0inutes. Data are expressed as mean ± SEM 14CL-cystine uptake in pmol/mg protein. No significant differences were found via
one-way ANOVA.
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Figure 3.4. System xc- antagonism prevents glutamate accumulation and
neuronal cell death. (A,B) Mixed cortical cultures were washed into BSS0 in
the presence or absence of 4-CPG (50 µM), LY367385 (50 µM), or YM298198
(10 µM). Eight hr later, supernatant was collected for measurement of
neuronal cell death (A) and glutamate accumulation (B). (*) indicates values
that are significantly different from control conditions (7.98 ± 0.89 % neuronal
injury; 9.56 ± 2.29 µM glutamate), while (#) represents a significant diminution
from GD-induced (A) neuronal injury or (B) glutamate accumulation [one-way
ANOVA followed by Student-Newman-Keul’s post hoc test. (n=11-12 cultures
from three different experiments)]. (Right) Representative phase micrographs
of mixed cortical cultures: (a) control; (b) 8 h GD; (c) GD + 4-CPG (50 µM); (d)
GD + YM298198 (10 µM).

87

To determine whether cell-autonomous/non-cell autonomous alterations in
system xc- activity underlie the initiation and/or progression of neuronal injury
following glucose deprivation, we prepared chimeric cultures consisting of WT
neurons plated on top of astrocytes derived from mice harboring a null mutation
in Slc7a11 (sut gene), which encodes for xCT, the light subunit of system xc(Chintala et al., 2005). In comparison to cultures containing both WT neurons
and astrocytes, neuronal injury following glucose deprivation is dramatically
reduced in chimeric cultures consisting of wild-type neurons plated on top of sut
astrocytes (Figure 3.6). Notably, the comparable LDH levels measured following
an NMDA exposure that results in 100% neuronal cell death (Figure 3.6 inset)
demonstrate that neurons plated on wild-type or sut astrocytes have similar
growth properties / cell densities and that wild-type neurons plated on sut
astrocytes are sensitive to NMDA. Finally, treatment of mixed cultures with IL-1β
to enhance xCT expression (Figure 3.7A) and system xc- activity in astrocytes
(Jackman et al., 2010a) — potentiates hypoglycemic neuronal injury (Figure
3.7B) such that injury now occurs at an earlier time point. This enhanced
neuronal injury is blocked by system xc- antagonism and/or by removal of the
substrate, L-cystine (Figure 3.7C).
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Figure 3.5. Hypoglycemic neuronal injury is dependent on cystine.
Cultures were deprived of glucose (4 hr) in a medium containing (GD) or lacking
(-AA) MEM amino acids save for supplementation with L-cystine (+CYSS) or Lmethionine (+MET). (*) indicates values different from control (2.87 ± 0.38 %
injury; 5.7± 0.74 µM glutamate) while (#) represents a significant diminution from
GD-induced (A) neuronal injury or (B) glutamate accumulation [one-way ANOVA
followed by Student-Newman-Keul’s post hoc test. (n = 4)]. (C) Cultures were
deprived of glucose (4 hr) in a medium containing (GD) or lacking (-AA) MEM
amino acids, L-cystine (-CYSS) alone, or L-methionine (-MET) alone. (*)
indicates values significantly different from control (0.55 ± 0.28 % injury); (#)
represents a significant diminution from GD-induced neuronal injury [one-way
ANOVA followed by Student-Newman-Keul’s post hoc test. (n=24 cultures from
six separate experiments)].
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Figure 3.6. Hypoglycemic neuronal injury is dependent on astrocyte system
xc- Chimeric cultures were obtained by plating WT neurons on astrocytes derived
from sut mice (hatched white bars). These and control cultures (WT neurons on WT
astrocytes; black bars) were washed into BSS0 (8 hr), glucose added (10 mM), and
then neuronal cell death determined 20-24 hr later. (*) indicates a significant withingroup difference, while (#) indicates a significant between-group difference [two-way
ANOVA followed by Bonferroni’s post hoc test. (n = 15-18 cultures from three
separate experiments)]. Inset: LDH absorbance values for chimeric and control
cultures treated with 250 µM NMDA for 20-24 hr.
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Figure 3.7. Enhanced system xc- activity potentiates hypoglycemic
neuronal injury. (A) Pure astrocytes (n = 3 from three experiments) were
incubated with IL-1β or vehicle for 6 hr, after which xCT mRNA expression
was assessed. (*) denotes values different from 0 hr [one-way ANOVA
followed by Dunnett’s post hoc test]. (B) Mixed cultures were incubated with
IL-1β for 20-24 hr then washed into BSS0. Glucose was added after 3.5 hr
and neuronal cell death determined 20-24 hr later. (*) indicates values
different from control (0 ng/ml IL-1β) [one-way ANOVA followed by Dunnett’s
post hoc test (n = 16 cultures from four separate experiments)]. (C) Mixed
cultures were incubated with IL-1β (GD + IL-1β) or vehicle (GD) for 20-24 hr,
then washed into BSS0 containing 4-CPG (50 µM) or LY367385 (50 µM) or
one lacking cystine (-CYSS) for 4 hr. (*) indicates values different from GD.
(#) represents a significant diminution from the IL-1β-mediated potentiation of
GD-induced neuronal injury [one-way ANOVA followed by Student-NewmanKeul’s post hoc test (n=6-16 cultures from four separate experiments)].
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3.5

Discussion
When blood glucose concentrations fall below 2 mM (normal = 4-7 mM),

brain glucose levels approach zero (Silver and Erecinska, 1994; Choi et al.,
2001),

precipitating neuronal injury. Neurons are highly sensitive to glucose

deprivation (Auer et al., 1984), whereas astrocytes have been demonstrated to
be more resistant (Monyer et al., 1989; Lyons and Kettenmann, 1998). This is in
accordance with the findings that rapid ATP depletion occurs exclusively in
neurons following glucose deprivation in vitro (Choi et al., 2008) and that
astrocytes contain glycogen stores that can be rapidly mobilized to meet
metabolic needs during conditions of glucose deprivation (Cataldo and
Broadwell, 1986; Swanson and Choi, 1993).
Despite this, cell death does not appear to be a direct result of energy
failure. In fact, several studies demonstrate that hypoglycemic neuronal injury
occurs secondary to glutamate excitotoxicity, as insulin-induced hypoglycemia
results in a two-three fold increase in glutamate accumulation in the rat
hippocampus and striatum as measured by microdialysis (Sandberg et al., 1986;
Silverstein et al., 1990). The data presented herein are in agreement with a twofold change in extracellular glutamate. Further, ionotropic glutamate receptor
antagonists are protective both in vivo and in vitro (Wieloch, 1985; Monyer et al.,
1989). Nevertheless, questions concerning the cellular source and molecular
mechanisms

surrounding

glutamate

hypoglycemia remain.
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release/accumulation

following

Although, in vivo deafferentation studies suggest some neuronal
contribution to hypoglycemic neuronal injury (Wieloch et al., 1985), we find that
synaptic release of glutamate did not contribute to toxicity, as glucosedeprivation-induced neuronal injury was not prevented by incubation with tetanus
toxin at a concentration that cleaves neuronal synaptobrevin-2 and blocks
depolarization-induced glutamate release/injury in our system (Taylor and
Hewett, 2002; Fogal et al., 2005b). This contrasts with earlier work demonstrating
40% protection against glucose deprivation-induced neuronal injury following
tetanus toxin exposure, albeit at a concentration 10x higher (Monyer et al., 1992).
Even when tested at the highest concentration utilized by Monyer and
colleagues, there was only 15% protection (data not shown), suggesting that in
our system synaptically-released glutamate is a minor source of excitotoxic levels
of glutamate. Additionally, we did not observe a reduction in glutamate (3H-Daspartate) uptake following 6 h of glucose deprivation. This agrees with literature
demonstrating no change in glutamate uptake in primary mouse cortical
astrocytes following 2 h of glucose deprivation (Bakken et al., 1998) and only a
20% loss after 24 h (Swanson and Benington, 1996). This begs the question as
to the cellular source of glutamate.
Studies have demonstrated that system xc, the antiporter that extrudes
glutamate while importing cystine, is an important contributor to the ambient
extracellular glutamate levels that bathe the central nervous system (Warr et al.,
1999; Baker et al., 2002b; Augustin et al., 2007; Massie et al., 2010b; De Bundel
et al., 2011). Importantly, the activity of system xc- has also been linked to
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excitotoxic neuronal injury in a number of paradigms (Piani and Fontana, 1994;
Barger and Basile, 2001; Qin et al., 2006; Fogal et al., 2007). For instance, the
export of glutamate via system xc- produces an excitotoxic necrosis that aids in
glioma tumor growth and invasion (Savaskan et al., 2008; Sontheimer, 2008) and
IL-1β-mediated hypoxic neuronal injury and 6-hydroxydopamine-mediated
dopaminergic toxicity are dependent on system xc- (Fogal et al., 2007; Jackman
et al., 2010; Massie et al., 2010a). We now report that hypoglycemic neuronal
toxicity is cystine-dependent and abrogated by system xc-- antagonism (Figure
3.5A, C) or when wild-type neurons were plated on top of sut (xCT-deficient)
astrocytes (Figure 3.6). Somewhat to our surprise, we were unable to measure
any changes in system xc--mediated cystine uptake in our model system (Figure
3.3). However, this is in accord with findings in mouse 3T3 cells (Sato et al.,
2004). Thus, basal activity of system xc- under conditions of energy deprivation
appears sufficient to facilitate neuronal injury. This is not unprecedented as the
glutamate concentrations needed to kill energy-deprived neurons are far less
than those required to kill healthy neurons (Novelli et al., 1988). Given that
extracellular levels of glutamate rise, we hypothesize that system xc- activity
initiates injury whereas secondary release of intracellular glutamate from dying
neurons propagates it (Fogal et al., 2005b). In support, we find that glucose
deprivation-induced neuronal injury is positively correlated with neuronal cell
density (r2=0.85), with sparse cultures routinely having less neuronal injury than
dense cultures (Figure 3.8).
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While elimination of astrocytic system xc- is sufficient to prevent glucose
deprivation-induced neuronal injury, we also found that enhancement of
astrocytic system xc- could potentiate injury (Figure 3.7B). While IL-1β was
utilized as a tool, it is notable that diabetics have increased IL-1β serum levels
compared to healthy individuals (Dogan et al., 2006). Given the increasing
evidence of crosstalk between the peripheral immune and central nervous
systems, it is intriguing to speculate that there may be some physiological
relevance.
Overall, our data demonstrate that inhibition of system xc- through
pharmacological or genetic means is sufficient to dramatically reduce excitotoxic
neuronal injury occurring secondary to glucose deprivation. These data highlight
the role of astrocytes in non-cell autonomous hypoglycemic neuronal injury and
further underscore their potential to serve as therapeutic targets for reducing
excitotoxic neuronal injury in vivo.
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Figure 3.8. Glucose deprivation-induced injury is dependent on
neuronal density. (A) Mixed cortical cultures containing neuronal densities
ranging from 1.5-3.5 hemispheres / 10 ml were washed thoroughly into
BSS0. Five and a half (n = 12) or eight hr later (n=6) , supernatant was
collected for measurement of neuronal cell death. Data are expressed as
raw LDH values as a function of neuronal density (A) and percentage of
neuronal cell death as a function of raw LDH values (B).
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CHAPTER 4
IL-1β-mediated neuroprotection against oxidant stress
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4.1

Summary

Astrocytes produce and export the antioxidant glutathione (GSH), which serves
as the principal source of substrate for neuronal GSH biosynthesis. Previously,
we found that interleukin-1β (IL-1β) enhances the expression of astrocyte system
xc-, the transporter delivering the rate-limiting substrate for GSH synthesis —
cyst(e)ine. Herein, we demonstrate that IL-1β mediates a system xc- and timedependent increase in extracellular GSH levels in cortical astrocyte cultures,
suggesting both enhanced synthesis and export. To determine whether this
increase could provide protection against oxidative stress in astrocytes and/or
neurons, pure astrocyte cultures, as well as, mixed cultures containing both
neurons and astrocytes were exposed to tert-butyl hydroperoxide (tBOOH).
Astrocytes were incubated with IL-1β (3 ng/ml) or vehicle for 48 hr, after which
cells were incubated with tBOOH (0.1- 0.7 mM; 2.5 h). tBOOH exposure
produced a concentration-dependent injury, which was significantly attenuated by
prior IL-1β treatment. Neurons and astrocytes in mixed cortical cultures were also
protected from a toxic tBOOH exposure (1.5 mM; 90-120 min) following
treatment with IL-1β. Further, astrocyte cultures were exposed to IL-1β (3 ng/ml;
0-24 h) after which mRNA and protein for molecules participating in GSH
biosynthesis, export, and metabolism were quantitatively determined. IL-1β
enhances mRNA and protein expression of xCT and decreases expression of γglutamyltranspeptidase,

the

ectopeptidase

responsible

for

extracellular

catabolism only. Taken together, these data suggest that IL-1β may increase
extracellular astrocytic GSH levels via the enhancement of substrate import
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coupled with the reduction in product catabolism. Hence, while the beneficial
effects of IL-1β are largely underappreciated, we show that IL-1β may be an
important stimulus for increasing astrocyte GSH production, and potentially, total
CNS antioxidant capacity.

4.2

Introduction
Depending on the context, alterations in astrocyte physiology following

neurological injury can promote survival or facilitate death (Liberto et al., 2004;
John et al., 2005). Inflammatory mediators like the cytokine interleukin-1β (IL-1β)
can act on astrocytes to induce changes in gene expression that modify
phenotype and function to produce these dichotomies (Zhao and Schwartz,
1998; Nguyen et al., 2002). For instance, endogenously produced IL-1β appears
necessary for the expression and maintenance of long term potentiation in
hippocampal slices (Schneider et al., 1998; Avital et al., 2003), while higher
concentrations — applied exogenously to mimic pathological expression —
inhibit it (Ross et al. 2003, Avital et al. 2003, Bellinger et al. 1993). Several
studies demonstrate that IL-1β-stimulated astrocytes support neuronal survival
via production of neurotrophic factors (Albrecht et al., 2002; John et al., 2005),
although others demonstrate that IL-1β can interfere with neurotrophin signaling
(Soiampornkul et al., 2008; Tong et al., 2008). Further, IL-1β has been shown to
both exacerbate injury and protect against excitotoxic stimuli [reviewed in
(Pinteaux et al., 2009)]. It is hypothesized that these dichotomous effects might
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result from cell-specific and/or concentration-dependent actions of IL-1β
(Pinteaux et al., 2009).
Additionally, work from our laboratory would suggest the protective versus
deleterious effects of IL-1β can be context-dependent. For instance, IL-1β
upregulates the activity of the cystine-glutamate amino acid antiporter system xcon astrocytes, which produces excitotoxic neuronal cell death only in the context
of energy deprivation (Fogal et al., 2007; Jackman et al., 2010). However, this
upregulation is in and of itself not cytotoxic. Interestingly, the same transporter
fluxing the glutamate which produces excitotoxicity during periods of energy
deprivation has a Janus-face and participates in the uptake of cystine for the
synthesis of the neuroprotective antioxidant molecule glutathione (Meister and
Anderson, 1983; Bannai and Tateishi, 1986).
Glutathione (GSH) is synthesized from the amino acids glutamate,
cysteine, and glycine via two sequential reactions catalyzed by γ-gammacysteinyl
ligase (GCL) followed by glutathione synthetase (GSS)(Meister and Anderson,
1983). Astrocytes release ≈10% of GSH/hour into the extracellular compartment
(Sagara et al., 1996; Minich et al., 2006), with most GSH being fluxed via
multidrug resistance protein 1 (Mrp1)(Hirrlinger et al., 2002). Once in the
extracellular space, γ-glutamyltranspeptidase (GGT1) initiates GSH catabolism,
which serves to provide precursors utilized by both neurons and astrocytes for
their GSH biosynthetic needs (Dringen et al., 1997; Kranich et al., 1998). In this
respect, astrocytes function as indispensible support cells by protecting against
oxidative insults (Tanaka et al., 1999; Shih et al., 2003; Jakel et al., 2007) since
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both astrocytes and neurons are more susceptible to oxidant-induced injury when
astrocytic GSH is deficient (Gegg et al., 2005).
Given the fundamentally protective nature of the inflammatory response,
we hypothesized that IL-1β-treated astrocytes could increase GSH. As such, the
ability of IL-1β to regulate the metabolic cycle of GSH in astrocytes and the
susceptibility of cells to oxidative stress in the presence and absence of IL-1β
was evaluated herein.

4.3

Materials and Methods

4.3.1 Cell culture

All media including media stock (MS), glial plating medium, mixed culture
plating medium, maintenance medium, and glucose-free balanced salt solution
(BSS) have been fully described in section 2.3.1.
Primary astrocyte cultures were derived from cerebral cortices of day 1-3
postnatal CD1 mouse pups (Charles River) as described (Trackey et al., 2001;
Jackman et al., 2010).
Mixed cortical cell cultures containing predominantly neurons and astrocytes
were prepared by culturing dissociated cells from embryonic day 15 mouse
fetuses onto a confluent layer of astrocytes in mixed culture plating media as
previously described (Trackey et al., 2001; Jackman et al., 2010). Experiments
were performed on mixed cortical cultures after 13-14 days in vitro.
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4.3.2 IL-1β Treatment

Astrocytes and mixed cultures were treated with recombinant murine IL1β (3 or 10 ng/ml respectively; R&D Systems) in an incubation buffer of MS
supplemented with 0.1% fatty-acid free BSA (Sigma) for the times indicated in
the figure legends. Cells were then returned to a humidified 37˚C normoxic (21%
O2) incubator containing 6% CO2.

4.3.3 Glutathione measurement

Total glutathione [GSx = reduced GSH + glutathione disulfide (GSSG)]
concentrations were determined using the GSH-Glo glutathione assay (Promega)
per manufacturer’s instruction. Media was collected for analysis of the
supernatant fraction and GSH-Glo reaction buffer was added to the cells.
Additional lysis buffer was made per manufacturer’s instructions and 200 µL was
added per well as a dilution factor to keep relative light units within the dynamic
range of the standards. All GSSG within the sample was converted to GSH with
the reducing agent TCEP-HCl (final concentration = 1 mM; 10 minutes; room
temperature; Thermo Scientific). One hundred microliters of each sample was
transferred to a 96-well plate and luciferin buffer was added for 10 minutes with
gentle agitation. Luciferase activity was measured in a luminometer (Optocomp
II; MGM Instruments). Cellular and tissue culture supernatant levels of GSx were
normalized to standards prepared in water and MS, respectively.
were linear over the range of 0–5 µM.
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Standards

4.3.4 Quantitative Real-time PCR (qPCR)

RNA was isolated and first-strand cDNA synthesized as previously
described (Jackman et al., 2010). qPCR was performed using mouse-specific
primer pairs [Taqman Gene Expression Assays, Applied Biosystems: xCT
(Mm00442530_m1), GCLC (Mm00802655_m1), GCLM (Mm00514996_m1),
GSS

(Mm00515065_m1),

Mrp1/Abcc1

(Mm00456156_m1),

GGT1

(Mm00492322_m1)] per manufacturer’s instructions. Reactions were run in the
Applied Biosystems Fast Real-Time PCR System and relative quantification
performed using the comparative cycle threshold method (∆∆CT), where CT
values of the transcript of interest were normalized to β-actin CT values from the
same sample, then compared to a calibrator CT value (untreated cells) to
determine the relative fold increase in mRNA. β-actin CT values were unaffected
by IL-1β treatment.

4.3.5 Immunoblotting

Protein expression was determined by Western Blot analysis. Astrocytes
in 24-well plates or T25 flasks were washed twice with ice-cold PBS then
incubated in lysis buffer [50 mM Tris, pH 8.0, 1.0% Nonidet-P40 (NP40), 150 mM
NaCl, and protease inhibitor cocktail (Roche)] for 30 minutes on ice. Cells were
harvested

by

scraping,

lysates

collected,

cellular

debris

removed

by

centrifugation (10,000 x g; 15 min; 4°C), and the resulting supernatants stored at
-20°C. After thawing, proteins were concentrated via ethanol precipitation. The
pelleted protein was resuspended in 1x urea buffer (50 mM Tris, pH 6.8, 2.5%
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glycerol, 5% SDS, 4 M Urea, 10 mM DTT, 0.02% bromophenol blue). Thirty µg
protein (BCA assay; Pierce) was separated by SDS-PAGE electrophoresis under
reducing conditions then electrophoretically transferred to a nitrocellulose
membrane (0.2 µm; Bio-Rad). Proteins of interest were detected using speciesspecific Western Breeze Immunodetection kits (Invitrogen) per manufacturer’s
instructions. Primary antibodies were incubated with membranes overnight at 4°
C at the following concentrations: α-GGT1 (1 µg/ml; mouse monoclonal; Santa
Cruz), α-β-actin (0.3 µg/ml; mouse monoclonal; Sigma) or α-GSS (1 µg/ml; rabbit
polyclonal; Abcam). Results were recorded on X-ray film (FujiFilm). Digitized
images were analyzed by computer-assisted densitometry (Gel-Pro Analyzer)
and GGT1 and GSS protein normalized to their respective β-actin levels.

4.3.6 Tert-butyl hydroperoxide (tBOOH) treatment

Following vehicle or IL-1β exposure, tBOOH (Acros Organics; final
concentration: 0.1-1.5 mM) was added to the cultures in an incubation buffer of
MS for the times indicated in the figure legends. Experiments were terminated
2.5 - 2.75 hr later by the addition of MTT. Tissue culture supernatant was
removed for measurement of lactate dehydrogenase (LDH; see section 4.3.7)
immediately before the addition of MTT. In mixed-culture experiments the
tBOOH-containing media was replaced with MS at the indicated times (0.5 – 2
hr). Supernatants were collected for measurement of LDH before media
replacement and immediately before addition of MTT to assess immediate and

104

delayed injury. Total neuronal injury was quantified via summation of early and
delayed LDH activity measurements.

4.3.7 Measurement of cell death and viability

Cell

death

was

quantitatively

determined

by

spectrophotometric

measurement of lactate dehydrogenase (LDH) as described previously (Uliasz
and Hewett, 2000). Data are expressed as a percentage of total neuronal or
astrocytic LDH activity (defined as 100%) determined by exposing parallel
cultures to 250 µM NMDA or 5 µM Calphostin C (Ikemoto et al., 1995),
respectively, for 20-24 hr. In mixed culture experiments, cell death values greater
than 100% reflect astrocytic LDH release such that all of the neurons and some
of the astrocytes are injured. Cell viability was quantified via colorimetric analysis
of Thiazolyl blue tetrazolium bromide (MTT; Sigma) reduction as previously
described (Lobner, 2000). Briefly, cultures were incubated with 40 µL MTT
solution/well (3 mg/ml MTT in PBS; final concentration = 300 µg/ml) for at least 4
h at 37 ºC. The MTT solution was carefully aspirated, crystals were solubilized in
acidified isopropanol (90% isopropanol; 10% 1 N HCl; 400 µL/well) and 200 µL
was transferred to a 96-well plate. Absorbance at 540 nm was measured with
690 nm background subtraction using a plate reader (SpectraMax M2, Molecular
Devices). Viability was expressed as a percentage of maximal MTT reduction
(i.e. highest absorbance = 100%) within the plate. Parallel cultures incubated with
5 µM Calphostin C for 24-48 hr defined a complete loss of viability (defined as
0%).
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4.3.8 Statistical Analysis

All statistical analyses were performed using GraphPad Prism (Version
4.03, GraphPad Software, Inc.) as described in each figure legend. Percentage
data were first transformed (arcsin square root) before analyses. For qPCR,
statistics were performed on the logarithmic retransformation (i.e. geometric
means) of 2-∆∆CT values. In all experiments, data are expressed as the mean ±
SEM and significance was assessed at p < 0.05.

4.4

Results
We previously demonstrated in a mixed cortical cell culture system that IL-

1β increased system xc- activity, then localized the phenomenon to occur
exclusively in astrocytes, not neurons or microglia (Fogal et al., 2007; Jackman
et al., 2010). Due to the enhanced delivery of cyst(e)ine via system xc-, it was
hypothesized that IL-1β would enhance intracellular glutathione levels.
Interestingly, following 24 and 48 hr of IL-1β exposure (3 ng/ml), astrocytes
exhibit a modest increase in intracellular GSH levels detectable at 24 h (Figure
4.1A). A dramatic increase in extracellular GSH levels is observed at both 24 and
48 h (Figure 4.1B) demonstrating enhanced synthesis and export of GSH.
Further, the enhancement in supernatant GSH is dependent on system xc- as this
effect is lost when astrocytes are treated concomitantly with IL-1β and 4-CPG (50
µM) but not YM298198 (10 µM) (Figure 4.2B). The former drug inhibits both
system xc- and mGluR1α, whereas the latter is a selective mGluR1α antagonist
(Fogal et al., 2007), demonstrating that system xc- antagonism alone prevents the
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increase in extracellular GSH. Importantly, 4-CPG and YM298198 have no effect
on intracellular GSH levels (Figure 4.2A).
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Figure 4.1. IL-1β increases supernatant GSH. Pure astrocytes (n = 6
from three experiments) were incubated with IL-1β (3 ng/ml) or vehicle
(-IL-1β) for 24-48 hr, after which total intracellular (A) and supernatant
(B) glutathione levels were assessed (GSx = GSH + GSSG). Data are
expressed as mean ± SEM total GSx (µM) compared to vehicle-treated
cells. An asterisk (*) denotes values different from untreated (-IL-1β)
astrocytes as assessed by two-way ANOVA followed by Bonferroni’s
post hoc test.
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Figure 4.2. The IL-1β-mediated increase in supernatant GSH is
dependent on system xc-.
Pure astrocytes (n = 4 from two
experiments) were incubated with IL-1β (3 ng/ml) or vehicle for 24 hr in
the presence or absence of 4-CPG (50 µM) or YM298198 (YM; 10 µM),
after which intracellular (A) or supernatant (B) GSx levels were
assessed. Data are expressed as mean ± SEM total GSx (µM)
compared to vehicle-treated (CTL) cells. An asterisk (*) denotes values
different from untreated astrocytes, while (#) represents a significant
diminution from the IL-1β-mediated enhancement of supernatant GSx
levels as assessed by one-way ANOVA followed by Student-NewmanKeul’s post hoc test.
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Given the interconnectedness between system xc- and cellular GSH levels, the
ability of IL-1β to influence other components of the GSH metabolic pathway was
assessed. Under basal conditions, the key metabolic transcripts involved in GSH
synthesis (GCLC, GCLM, GSS), export (Mrp1), and extracellular catabolism
(GGT1) are all expressed in primary cortical mouse astrocytes (Figure 4.3A).
Consistent with previous findings, IL-1β (3 ng/ml; 0-24 h) elicits a time-dependent
increase in xCT mRNA in astrocytes that peaks at 4 h then slowly declines over
time [Figure 4.3B and (Jackman et al., 2010)]. No notable changes in the
expression of GCLC, GCLM, or Mrp1 were observed (Figure 4.3C,D,F), and the
biological significance of the small (≈1.5-fold), but statistically significant increase
in GCLC mRNA remains to be ascertained. The relative expression of GSS
mRNA exhibits a time-dependent increase that peaks after 8 hr IL-1β exposure,
followed by a decrease and return to baseline levels by 24 hr (Figure 4.3E).
Finally, an ≈80% reduction in GGT1 mRNA expression is observed 4 hr after IL1β treatment which persists until 24 hr, the final time point assessed in these
studies (Figure 4.3G). Since we had previously demonstrated that the IL-1βmediated increase in xCT mRNA was paralleled by an increase in xCT protein
expression (Jackman et al., 2010), protein levels of GSS and GGT1 following IL1β treatment were evaluated. Consistent with the qPCR data, 12-24 hr IL-1β
treatment reduces GGT1 protein levels (Figure 4.4), yet this treatment fails to
alter GSS protein expression (Figure 4.5).
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Figure 4.3. IL-1β regulates xCT, GSS, and GGT1 mRNA
expression. (previous page)
(A) Total RNA was isolated from unstimulated astrocytes, reverse
transcribed, and PCR performed using specific primers for xCT,
GCLC, GCLM, GSS, Mrp1, and GGT1 in separate reactions. ( All
reactions were for 33 cycles save for GGT1 and β-actin which were for
31 and 23 cycles respectively). (B-G) Pure astrocytes (n=3-6) were
treated with IL-1β (3ng/ml) or its vehicle for the indicated durations and
relative mRNA expression assessed via qPCR. Data are expressed as
mean ± SEM fold change in mRNA compared to untreated cells (0 hr).
An asterisk (*) denotes values different from untreated cells as
assessed by one-way ANOVA.
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Figure 4.4. IL--1β
1β downregulates GGT1 protein expression.
Pure astrocyte cultures were incubated with vehicle or 3 ng/ml IL
IL1β for 12-48
48 hr. Representative of 5-6
6 western blots (GGT1). Films
were scanned and densitometry performed using Gelpro Analyzer
software and GGT1 protein levels were normalized to their
corresponding β -actin
actin protein levels and expressed as a fold
change (mean ± SEM) relative to control (0 h; set to 1).
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Figure 4.5 IL-1β
1β does not alter GSS protein expression. Pure
astrocyte cultures were incubated with vehicle or 3 ng/ml IL
IL-1
1β for 12-48
hr. Representative of 4
4-6 western blots. Films were scanned and
densitometry performed using Gelpro Analyzer software and GSS protein
levels were normalized to their corresponding β-actin
actin protein levels and
expressed as a fold change (mean ± SEM) relative to control (0 h; set to
1).
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It was hypothesized that the IL-1β-mediated changes in GSH metabolism could
confer protection against an oxidative stressor. Since catalase cannot neutralize
organic hydroperoxides, tert-butyl hydroperoxide (tBOOH) was utilized as its
elimination is dependent on GSH and GSH-peroxidase (Dringen et al., 1998;
Kussmaul et al., 1999). Depletion of GSH via a 24 hr incubation of astrocytes
with buthionine sulfoximine (BSO), a γ-glutamylcysteinyl ligase inhibitor, can
render a sub-lethal concentration of tBOOH (0.3 mM) toxic demonstrating the
necessity of GSH for tBOOH elimination in our model system (Figure 4.6).
Astrocytes were treated with IL-1β or vehicle for 48 hr then incubated with
tBOOH (0-0.7 mM) for 2.5 hr after which cell death and cell viability were
evaluated. tBOOH exposure produces a concentration-dependent injury which is
attenuated by IL-1β treatment (Figure 4.7), implicating significant glioprotective
properties of IL-1β. Finally, mixed cultures were treated with IL-1β (10 ng/ml) or
vehicle for 48 hr then incubated with tBOOH (1.5 mM) for 30-120 min, after which
a sample of tissue supernatant was collected for LDH analysis, the media was
replaced with MS, and injury allowed to progress until 165 min had elapsed at
which point MTT was added to the wells to terminate the experiment. Little injury
occurs during the acute tBOOH exposure as demonstrated by minor LDH
accumulation in the media (gray bars) prior to media replacement. Notably, injury
evolves over time. Neuronal injury becomes statistically significant after tBOOH
exposure for 60-120 minutes in untreated cultures or after a 120 minute exposure
in IL-1β treated cultures (Figure 4.8A). Importantly, neurons are protected against

115

a 90 and 120 min exposure to tBOOH if they were previously incubated with IL1β (Figure 4.8A). Further, a 120 min exposure to tBOOH injures both neurons
and astrocytes as demonstrated by visual inspection of the astrocyte monolayer
and by neuronal cell death percentages greater than 100%. Importantly,
pretreatment with IL-1β attenuates the toxicity of tBOOH in mixed cultures at this
time point (Figure 4.8B).
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Figure 4.6. tBOOH toxicity is GSH-dependent. (A) Pure astrocytes
were incubated with BSO (3-300 µM) or vehicle for 24 hr, after which
intracellular GSH levels were assessed. Data are expressed as
mean ± SEM GSH expressed as a percent of control levels (0 µM
BSO). An asterisk (*) denotes values different from untreated
astrocytes as assessed by one-way ANOVA followed by Dunnett’s
post hoc test. n = 4 from 2 experiments. (B) Pure astrocytes were
incubated with BSO (3-100 µM) or vehicle for 24 hr, after which
cultures were exposed to a sub-lethal concentration of tBOOH (0.3
mM) for 3.5 hr. Data are expressed as mean ± SEM percent viable
astrocytes. n = 6 from three experiments. An asterisk (*) denotes
values different from untreated (-tBOOH) astrocytes as assessed by
two-way ANOVA followed by Bonferroni’s post hoc test.
117

% ASTROCYTE CELL DEATH

A
60

- IL-1β
β
+IL-1β
β

40

*

*

20

0
0

0.1

0.5

0.7

B

% VIABLE ASTROCYTES

tBOOH (mM)

100

- IL-1β
β
+IL-1β
β

75
50

*

*

25
0
0

0.1

0.5

0.7

tBOOH (mM)

Figure 4.7. IL-1β protects astrocytes against tBOOHmediated oxidative injury. Pure astrocytes were incubated with
IL-1β (3 ng/ml) or vehicle (-IL-1β) for 48 hr, after which cells were
incubated with tBOOH (0.1-0.9 mM; 2.5 h). (A) Supernatant was
collected for LDH analysis of cell death (A) and oxidative injury
was terminated with the addition of MTT to assess cell viability.
(B) Data are expressed as mean ± SEM percent viable
astrocytes. An asterisk (*) denotes values different from
untreated astrocytes as assessed by two-way ANOVA followed
by Bonferroni’s post hoc test. n = 8-14 from two-three
experiments.
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Figure 4.7. IL-1β protects against tBOOH-mediated oxidative
injury in mixed cultures. Mixed cortical cultures were incubated
with IL-1β (10 ng/ml) or vehicle (-IL-1β) for 48 h, after which cells
were incubated with tBOOH (1.5 mM) for 90-120 minutes, after
which the media was replaced with MS. The experiment was
terminated after 165 min when media was collected for
assessment of cell death via LDH release (A) and MTT was
added to the cultures to assess cell viability (B). Gray bars
represent neuronal cell death arising from the acute tBOOH
exposure. Data are expressed as mean ± SEM percent neuronal
cell death and viability. An asterisk (*) denotes values different
from untreated astrocytes as assessed by two-way ANOVA
followed by Bonferroni’s post hoc test. n = 4-6 from three
experiments.
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4.5

Discussion
Maintenance of a reduced intracellular environment is essential to cell

survival as altered redox status in astrocytes in favor of pro-oxidant conditions
impairs glutamate clearance via GLAST and GLT1 (Trotti et al., 1997), disturbs
cell signaling and gene expression, and can damage nucleic acids, proteins, and
lipids. Our laboratory has previously published that IL-1β regulates astrocyte
system xc-, a cystine-glutamate antiporter, essential for delivering cyst(e)ine the
rate-limiting substrate for the synthesis of the antioxidant molecule GSH (Fogal et
al., 2007; Jackman et al., 2010). However, the physiological consequences of
the IL-1β-mediated enhancement in system xc- were unknown and it remained to
be determined whether IL-1β regulated GSH levels in astrocytes as has been
shown for other cell types following induction of system xc- (Sato et al., 1995a;
Sasaki et al., 2002).
Since circulating GSH is unable to penetrate the blood brain barrier
(Cornford et al., 1978), GSH within the CNS must be generated in situ. In the
CNS, astrocytes function as the predominant provider of GSH and understanding
the modulation of GSH levels is of great import. Alterations in GSH content could
directly influence astrocytic GSH flux, utilization of GSH precursors by other cell
types, and confer resistance against or enhance vulnerability to oxidative insults.
In our studies, IL-1β enhanced extracellular levels of GSH and these changes
were associated with enhanced expression of xCT and reduced expression of
GGT1. Importantly, the IL-1β-mediated changes in astrocytic antioxidant capacity
reduces susceptibility to the oxidative stressor tert-butyl hydroperoxide in purified
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astrocyte cultures and in mixed cortical cultures (Figures 4.7, 4.8).
IL-1β and other cytokines have been demonstrated to participate in the
regulation of antioxidant levels in non-neural tissue (Kayanoki et al., 1994;
Antras-Ferry et al., 1997). In non-neural cells including mouse endothelial cells
(Urata et al., 1996) and endometrial stromal cells (Lee et al., 2009),

IL-1β

increases intracellular GSH levels. Our data are consistent with the previously
reported observations that intravenous administration of IL-1β decreases GGT1
activity in the rat hippocampus within 2 h (Kaiser et al., 2006) and in a human
astrocytoma cell line following a 24 h exposure to IL-1β (Malaplate-Armand et
al., 2000).
The notion that neuroprotection could be mediated by an inflammatory
mediator is not unprecedented, as positive effects of IL-1β in the CNS and
periphery have already been reported. For example, IL-1β protects mice against
lethal challenge via radiation or infection when administered 20-24 hr prior to the
insult (Neta et al., 1986; Schwartz et al., 1987; van der Meer et al., 1988). Within
the brain, chronic overexpression of IL-1β ameliorates pathology observed in the
hippocampus in a mouse model of Alzheimer’s disease (Shaftel et al., 2007). IL1β enhances neuronal sprouting and/or regeneration in vitro and in the
hippocampus and ventral tegmental nucleus in vivo (Fagan and Gage, 1990;
Wang et al., 1994; Temporin et al., 2008). IL-1β-deficient mice have impaired
blood brain barrier repair compared to their WT counterparts following
corticectomy as assessed via extravasation of IgG into brain parenchyma (Herx
and Yong, 2001) and remyelination is impaired in these mice secondary to
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delayed differentiation/maturation of oligodendrocytes (Mason et al., 2001; Vela
et al., 2002). In a similar vein TNF-α, which is induced by IL-1β, promotes
oligodendrocyte progenitor maturation and remyelination (Arnett et al., 2001).
While the mechanisms are not yet fully elucidated one can speculate that some
protective effects of IL-1β can be attributed to transcriptional regulation of genes
intimately involved in neuronal and glial proliferation and/or survival including
nerve growth factor (NGF) and ciliary neurotrophic factor (CNTF) among others
(Friedman et al., 1990; Spranger et al., 1990; Albrecht et al., 2002).
It should be noted that a 24 hr exposure of astrocytes to IL-1β alters the
expression of approximately 1400 hundred genes (John et al., 2005). In addition
to modulating the expression of trophic factors, the beneficial effects of IL-1β may
arise via cytokine influence on antioxidant systems. In rat astroglial cultures,
LPS-activated microglia induce numerous proteins in astrocytes with antioxidant
properties including SOD2, peroxiredoxins, and glutathione S-transferase, and
these changes are associated with protection from H2O2-induced oxidative stress
(Röhl et al., 2008). IL-1β has been demonstrated to alter metallothionein
expression in human fetal astrocytes (John et al., 2005). CNTF, a growth factor
induced by IL-1β, increases the expression of the astrocyte-specific glutathioneS-transferase (GST-µ) (Levison et al., 1996) important in the conjugation of
harmful compounds to GSH and subsequent extrusion from the cell. Additionally,
IL-1α regulates MnSOD expression (Mokuno et al., 1994) and IL-1β induces
ceruloplasmin (Chang et al., 2001; Kuhlow et al., 2003) -- a copper and iron
chelator -- potentially limiting the iron-mediated generation of reactive species via
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Fenton chemistry.
Given the opposing nature of “typical” pro- and anti-inflammatory
mediators, it raises the intriguing possibility that specific cytokines regulate
particular components of a system, and that single cytokines or combinations of
cytokines may be responsible for the fine-tuning of antioxidant status based on
the timing, concentration, and/or kinetics of cytokine expression in specific cell
types. In support of this notion, in our studies and those by others IL-1β reduces
GGT1 expression/activity, whereas TNF-α can induce GGT1 expression and
activity (Reuter et al., 2009). In the liver and liver-derived cell line, IL-1β, and IL-6
can induce Mrp1 mRNA expression (Lee and Piquette-Miller, 2001, 2003;
Cherrington et al., 2004), but in primary rat astrocytes TNF-α, but not IL-1β or IL6, can increase Mrp1 (Ronaldson et al., 2010).
The production of the antioxidant GSH is of obvious importance for the
maintenance of cellular health. Although, additional studies are necessary to
elucidate the role of IL-1β in post-transcriptional regulation of GSH metabolism,
this pleiotropic cytokine unequivocally enhances GSH levels in part via regulation
of xCT and GGT1. These findings underscore the importance of understanding
the effects of cytokines in various physiological as well as pathophysiological
contexts. Ironically, while this pathway allows the CNS to rapidly upregulate GSH
in response to an oxidative challenge, it also holds the potential to exacerbate
CNS pathology as a consequence of increasing extracellular glutamate levels
and the risk of excitotoxicity. The balance between these two possible outcomes
must always be kept in mind when considering the physiological consequences
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of alterations in system xc- expression and function. Indeed, as Shaftel and
colleagues articulated so eloquently: “IL-1 can no longer be regarded as simply
the villain in the setting of brain injury and disease, but instead might be
understood as a factor that can influence the balance between beneficial and
detrimental outcomes” (Shaftel et al., 2008). The same is certainly holds true for
system xc- .
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CHAPTER 5
Putative Mechanism of Regulation
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5.1

Summary

We recently demonstrated that interleukin-1β (IL-1β) increases system xc- activity
in mixed cortical cell cultures, resulting in an increase in hypoxic neuronal injury
when glutamate clearance is impaired. System xc- activity is also deleterious in
the context of glucose deprivation in the presence of competent glutamate
uptake. Interestingly, when cultures are not under conditions of energy
deprivation, the enhancement in system xc- by IL-1β produces an accumulation of
glutathione in the extracellular space, which can protect both neurons and
astrocytes against oxidant-induced injury. Given the context-dependent effects of
system xc- it is important to understand the mechanisms by which this transporter
is regulated. Herein, we demonstrate that NF-κB appears to be a negative
regulator with inhibition of NF-κB via BAY-11-7082 enhancing the expression of
xCT in a manner that potentiates the effects of IL-1β. The protein kinase A/C/G
inhibitor H7 prevents the IL-1β-mediated enhancement in xCT mRNA expression.
Interestingly, xCT mRNA expression is enhanced by application of PMA and
dBcAMP, activators of PKC and PKA, respectively, but not by 8-Br-cGMP.
Finally, the concentrations of H7 were efficacious as it could block the PMA and
dBcAMP-mediated

enhancement

in

xCT

expression.

Overall,

our data

demonstrate that NF-κB is not involved in system xc- regulation by IL-1β and that
protein kinase A and/or C likely participates in the regulation of xCT in the
presence and absence of IL-1β.
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5.2

Introduction
This thesis documents that IL-1β enhances xCT mRNA and protein

expression along with the activity of astrocytic system xc- (Chapter 2), yet the
mechanism(s) of regulation have not been elucidated. It has been well
documented that many agents induce xCT expression and/or system xc- activity
including: electrophiles like diethyl maleate (Bannai, 1984a), cystine deprivation
and deprivation of other amino acids (Bannai and Kitamura, 1982), oxidative
stress via the generation of reactive species (Bridges et al., 2001; Dun et al.,
2006), oxygen (Bannai et al., 1989), oxidized low-density lipoprotein (LDL) (Sato
et al., 1995b), the HIV tat (transactivation of transcription) protein (Bridges et al.,
2004), Aβ (Qin et al., 2006), erythropoietin (Sims et al.), dBcAMP (Gochenauer
and Robinson, 2001; Seib et al., in press), and pertinent to this thesis, the
inflammatory mediators LPS and TNF-α (Sato et al., 1995a).
Transcriptional regulation of xCT has been demonstrated in non-neural
cells (Itoh et al., 1999; Sato et al., 2001; Sasaki et al., 2002; Qiang et al., 2004;
Sato et al., 2004) and the xCT 3’ UTR contains numerous AU-rich elements (our
unpublished observations), the occupation of which by trans-acting factors is
known to influence mRNA stability (Brennan and Steitz, 2001). The xCT
promoter contains several cis-acting regulatory elements including four
antioxidant response elements (ARE, also referred to as the electrophile
response element, EpRE), two amino acid response elements (AARE), and
putative AP-1 and NF-κB binding sites (Sato et al., 2000; Sato et al., 2001;
Sasaki et al., 2002; Sato et al., 2004). Depletion of GSH facilitates the nuclear
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translocation of the transcription factor NF-E2-related factor (Nrf2), which
regulates gene expression through its subsequent interaction with AREs (Itoh et
al., 1999; Qiang et al., 2004). The transcription factor ATF4 mediates the
enhancement of xCT following amino acid deprivation via binding to the AARE
(Sato et al., 2004). Other mechanisms by which system xc- is regulated remain to
be ascertained.

5.3

Materials and Methods

5.3.1 Cell culture

Cell culture media, experimental buffer compositions, and primary
astrocyte cultures have been previously described (see section 2.3.1).

2.3.2 Cell Treatment

Cells were treated with recombinant murine IL-1β, dBcAMP, PMA, or 8-BrcGMP for the times indicated in the figure legends in an incubation buffer of MS
supplemented with 0.1% fatty-acid free BSA (Sigma). Cells were then returned to
a humidified 37˚C normoxic (21% O2) incubator containing 6% CO2.

5.3.3 qPCR

RNA isolation and qPCR have been described in detail previously (see section
2.3.4 and 2.3.5).
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5.4

Results
Since signaling in response to IL-1β in astrocytes is preferentially

mediated by NF-κB (Srinivasan et al., 2004) and the xCT promoter contains a
putative NF-κB consensus sequence (Sato et al., 2001), NF-κB was evaluated as
a potential transcriptional regulator of xCT. NF-κB activation was assessed by
nuclear translocation of p65 which was rapid and robust, with peak p65 nuclear
translocation occurring 15 minutes after IL-1β stimulation then declining over time
and returning to baseline levels within 60 minutes (Figure 5.1). Astrocytes were
incubated with the NF-κB inhibitor BAY 11-7082, which inhibits phosphorylation
of IκB-α (Pierce et al., 1997) for 1 hour after which IL-1β was added to the
cultures for 6 h. Importantly, 30 µM BAY 11-7082 is sufficient to block IL-1βinduced translocation of p65 into the nucleus (Figure 5.2A). Inhibition of NF-κB
signaling by BAY 11-7082 did not block the IL-1β-mediated enhancement of xCT
expression, rather, it potentiated the effects of IL-1β (Figure 5.2B). Similar
enhancements in xCT mRNA expression were obtained in experiments utilizing
an alternate NF-κB inhibitor PDTC (Appendix Figure A3). These findings are
consistent with the observation that low concentrations of LPS induce xCT
expression in the absence of NF-κB activation (Sato et al., 2001), suggesting that
changes in xCT gene-expression can occur independently of TLR4-mediated NFκB activation.

Parallel studies were conducted utilizing a variety of inhibitors to identify
potential candidates involved in the IL-1β-mediated enhancement of xCT mRNA.
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While not an exhaustive screen, the only inhibitor tested that blocked the effect
was H7, a pan-protein kinase A/C/G inhibitor (Figure 5.3).
To elucidate which protein kinase has the potential to enhance xCT
expression astrocytes were incubated with dibutyryl cAMP (dBcAMP), phorbol
12-myristate 13-acetate (PMA), and 8-Br-cGMP to activate PKA, PKC, and PKG,
respectively. dBcAMP and PMA enhance xCT mRNA expression whereas 8-BrcGMP does not (Figure 5.4). Importantly, the concentration of H7 utilized in the
previous experiment is efficacious as it is sufficient to block the IL-1β- , dBcAMP-,
and PMA-mediated enhancement in xCT mRNA (Figure 5.5).
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Figure 5.1.. Time course of NF
NF-κB activation by IL-1β. (A) Pure astrocyte cultures
were incubated with vehicle (0 min) or 3 ng/ml IL
IL-1β (15-60
60 min). Cells were
harvested, nuclear and cytoplasmic fractions isolated, and 10 mg protein was
separated by SDS-PAGE
PAGE (12% gel). Western blot analysis was performed using
antibodies directed against p65 (NF
(NF-κB), b-actin
actin (loading control), and Histone H3
(nuclear marker). Representative of six blots. (B) Films were scanned and
densitometry performed using Gelpro Analyzer software. Nuclear p65 protein levels
were normalized to their corresponding β-actin
actin protein levels and expressed as a fold
increase (mean ± SEM) over control (0 min; set to 1). An asterisk (*) denotes values
that are significantly increased over control as assessed by one
one-way
way ANOVA followed
by Dunnett’s post hoc test of the arc sin square ro
root
ot transformed values (n = 6).
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Figure 5.2 NF-κB
κB may negatively regulate xCT expression. (A)
Astrocytes were incubated with vehicle or BAY 11-7082 (30 µM) for 30 min
after which IL-1β
1β or vehicle was added for 30 min then nuclear
accumulation of p65 was assessed via immunocytochemistry. (B)
Astrocytes (n=3) were incubated with various concentrations of BAY 1111
7082 for 1 hour after which IL-1β or vehicle was added for 6 hr then xCT
mRNA assessed via qPCR. Data are expresse
expressed
d as mean ± SEM fold
change in xCT mRNA compared to untreated cells.
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Figure 5.3. The pan-PKA/PKC/PKG inhibitor H7 blocks the IL-1βmediated enhancement in xCT mRNA. Astrocytes (N=2) were incubated
with the kinase inhibitors listed for 1 hour after which IL-1β (3 ng/ml) was
added for 5 hr and xCT mRNA assessed via qPCR. Data are expressed as
mean ± SEM fold change in xCT mRNA compared to IL-1β-treated cells (IL1β). Inhibitor concentrations were as follows SB203580, 3µM; SP600125, 30
µM; UO126, 10 µM; PD98059, 50 µM;H89, 1 µM; Calphostin C (CalC), 1µM;
KT5823, 1.5 µM; H7, 30 µM; LY294002, 5 µM.
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Figure 5.4. PKA and PKC activation induce xCT expression. Pure
astrocytes (n=2) were treated with IL-1β (3ng/ml), dBcAMP (500 µM), PMA
(100 nM), 8-Br-cGMP (300µM) or its vehicle for 8 hr and xCT mRNA
assessed via qPCR. Data are expressed as mean ± SEM fold change in
xCT mRNA compared to untreated cells (CTL).
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Figure 5.5. Inhibition of PKA/PKC prevents the IL-1β mediated induction of
xCT. Pure astrocytes (n=2) were incubated with H7( 30 µM; 1 hr) after which IL1β (3 ng/ml), PMA (100 nM) or its vehicle were added for 6 hr or dBcAMP (500
µM) was added for 8 hr and xCT mRNA assessed via qPCR. Data are
expressed as mean ± SEM fold change in xCT mRNA compared to untreated
cells (CTL).
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5.5

Discussion
This data presented herein suggests that NF-κB is not the transcription

factor responsible for the enhancement of xCT mRNA and may actually function
as a negative regulator of system xc-. We posit that there may be a constitutively
active form of NF-κB in astrocytes, or in a distinct subpopulation of astrocytes, as
constitutive NF-κB activation has been reported in mature B cells (Doerre and
Corley, 1999), thymocytes (Korner et al., 1991), some thymomas (Hemar et al.,
1991) and monocytic cell lines (Griffin et al., 1989). Importantly, constitutive
expression of NF-κB has been described in the CNS in some hippocampal and
cortical

neurons

as

measured

by

luciferase

reporter

assays

and

immunofluorescence (Kaltschmidt et al., 1994; Bhakar et al., 2002). This notion is
plausible as p65 is observed in the nucleus in the absence of stimulation after
incubation with the nuclear export inhibitor leptomycin B suggesting that NF-κB
shuttles between the nucleus and cytoplasm in astrocytes (Zhai et al., 2004). As
such, the role of NF-κB in regulation of xCT warrants further study and astrocytes
derived from mutant mice containing a dominant negative form of IκB localized
exclusively to astrocytes (GFAP-IκB-DN) or IKK knockout mice might be
particularly useful for future inquiries (Li et al., 2000; Herrmann et al., 2005;
Zhang et al., 2005).
It should be noted that PMA and PKA can activate NF-κB (Shirakawa et
al., 1989; Shirakawa and Mizel, 1989; Ghosh and Baltimore, 1990), yet activation
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of NF-κB by TNF-α appears to occur in a PKC-independent fashion (Meichle et
al., 1990). It has previously been reported that a chronic exposure of astrocytes
to dBcAMP for seven to ten days enhances xCT mRNA and protein expression
and system xc- activity (Gochenauer and Robinson, 2001; Seib et al., in press),
yet acute induction of xCT by dBcAMP to the best of our knowledge has not been
previously reported. There is also evidence for PKC-mediated regulation of
system xc- activity levels in neutrophils where xCT mRNA is enhanced after
incubation with PMA (Sakakura et al., 2007). However Tang and colleagues
demonstrate a PMA-mediated reduction in cystine uptake in rat cortical
astrocytes at identical concentrations (100nM) to those utilized in the studies
presented herein (Tang and Kalivas, 2003).

Further studies are required to

understand the discrepancies between Tang’s studies and the data presented in
this dissertation.
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CHAPTER 6
Conclusion, Discussion, and Future Directions

138

6.1

Main Findings
The main findings of this dissertation are that: (1) IL-1β enhances system

xc- activity and xCT mRNA and protein expression in astrocytes, but not neurons
or microglia. Further, there is some specificity to this response as IL-1β does not
influence expression of the system xc- heavy chains (4F2hc or RBAT), LAT2 (the
light chain of the system L amino acid transporter), or the predominant glutamate
transporters in astrocytes (EAAT1/GLAST and EAAT2/Glt-1). (2) The activity of
astrocytic system xc- is contributory to neuronal injury following energy
deprivation (specifically the IL-1β-mediated enhancement of hypoxic injury and
hypoglycemic injury), and (3) astrocytic system xc- protects both astrocytes and
neurons against cytotoxicity caused by oxidant stress (tert-butyl hydroperoxide).

6.2

Cell specificity: The importance of astrocytes
Astrocytes are the most numerous cell type in the brain and while

originally viewed simply as structural support for neurons, we are continuing to
learn how astrocyte physiology is critical for the maintenance of homeostasis, in
general, and neuronal physiology specifically. In addition to providing structural
support, astrocytes provide metabolic support via delivery of energy substrates
and buffering of pH and K+, promotion of growth, regulation of synaptogenesis
and synaptic maintenance, modulation of neuronal excitability, participation in the
formation and maintenance of the blood brain barrier, and regulation of vascular
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tone and microcirculation such that functional hyperemia -- the coupling of
cerebral blood flow and neuronal activity -- occurs. (Ransom and Sontheimer,
1992; Ullian et al., 2001; Nedergaard et al., 2003; Maragakis and Rothstein,
2006; Markiewicz and Lukomska, 2006; Sidoryk-Wegrzynowicz et al., 2011).
Organizationally, astrocytes only overlap in a narrow interface, such that
they are predominantly arranged into non-overlapping domains (Bushong et al.,
2002; Halassa et al., 2007b). Despite the non-overlapping organization of
astrocytes, there is significant inter-astrocyte communication via a

‘glial

syncytium’ which creates an integrated functional unit capable of distributing
energy substrates, metabolites, and second messengers widely (Scemes and
Spray, 2004). This may be particularly important since astrocytes are a
heterogeneous population [for a detailed review see (Hewett, 2009; Zhang and
Barres, 2010)] and extensive coupling likely fosters coordinated responses over
long distances.
Further, astrocytes participate in gliotransmission via the release of
neurotransmitters such as glutamate and other neuromodulators (Nedergaard,
1994; Parpura et al., 1994; Haydon, 2001) enabling bidirectional communication
between neurons and astrocytes. This spatial and functional association of the
pre- and post-synaptic neurons and the astrocyte processes ensheathing the
synapse is referred to as the tripartite synapse (Halassa et al., 2007a). Important
in this respect is the finding that a single astrocyte contacts 300-600 neuronal
dendrites (Halassa et al., 2007b) and that its foot processes can ensheath up to
100,000 synapses (Bushong et al., 2002; Ogata and Kosaka, 2002). This
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structural organization perfectly positions the astrocyte to activate neighboring
neurons and influence neurotransmission (Nedergaard, 1994; Parpura et al.,
1994).
In addition to releasing glutamate, astrocytes remove glutamate from
synaptic and extra-synaptic spaces to reduce the probability of excitotoxic
neuronal injury. Glutamate is converted to glutamine, by astrocytic glutamine
synthetase (Norenberg and Martinez-Hernandez, 1979) prior to being shuttled to
neurons for the re-synthesis of the neurotransmitter glutamate (Danbolt, 2001). In
a similar vein, as discussed earlier astrocytes synthesize and export the
antioxidant molecule glutathione which is broken down extracellularly and utilized
by neurons and glia for cellular antioxidant defense. The protective capacity of
astrocytes is remarkable -- with only a small number of astrocytes (<1 % of total
cell number) required to protect neurons against an oxidative stress-mediated
injury in mixed neuron-glia co-cultures (Shih et al., 2003). Additionally, the ability
of astrocytes to support and maintain neuron health may be attributed to the
ability of the astrocyte to release numerous growth factors such as NGF, BDNF,
PDGF, and more (Raff et al., 1988; Rudge, 1993).
Despite the important homeostatic functions of astrocytes in the
developing brain and in the repair of an injured CNS, astrocytic responses can
also promote injury. In particular, astrocytes can be activated by glutamate or
inflammatory mediators to induce expression and/or release factors that may
participate in neuronal injury and/or neurodegeneration. Two mediators include
COX2 and NOS2 which have the potential to contribute to neuronal and/or glial
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injury (Galea et al., 1992; Simmons and Murphy, 1992; Hewett et al., 1993;
Molina-Holgado et al., 2000; Maragakis and Rothstein, 2006).
Results from this dissertation extend the role of astrocytes in both
cytotoxicity and neuroprotection. Microarray data shows that a 24 h exposure of
human fetal astrocytes to 10 ng/ml IL-1β alters the expression of approximately
1400 genes (John et al., 2005). The alterations in astrocyte gene expression in
response to IL-1β may be beneficial or deleterious depending on features such
as the concentration, timing, and longevity of release (i.e., acute or chronic
enhancement in expression), and the specific cell-type activated.

6.3

Working model for contributions of system xc- to injury and

protection (Figure 6.1)
System xc- functions to exchange intracellular glutamate for extracellular
cystine. Under physiological conditions, the activity of the transporter does not
facilitate the toxic accumulation of glutamate (Baker et al., 2002c; Augustin et al.,
2007; Featherstone and Shippy, 2008; Massie et al., 2010b; De Bundel et al.,
2011), but rather contributes to basal extracellular glutamate levels and regulates
intracellular GSH levels. However, when glutamate uptake is impaired, as it is
under hypoxic conditions the increased activity of system xc- via its regulation by
the cytokine IL-1β results in the accumulation of extracellular glutamate and
subsequent excitotoxic neuronal cell death (Fogal et al., 2007). Our laboratory
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postulates that similar alterations in system xc- activity may contribute to neuronal
injury in vivo following cerebral ischemia in response to the upregulation of IL-1β.
To our surprise, system xc- also contributes to excitotoxic neuronal injury
under hypoglycemic conditions in the absence of a detectable impairment in
glutamate uptake. Further, IL-1β is not required for this toxicity. Thus, it appears
that basal levels of glutamate released via system xc- are sufficient to initiate
injury when the energy substrate glucose is unavailable. What remains to be
elucidated is precisely how system xc- can release sufficient quantities of
glutamate that are capable of overwhelming functional glutamate reuptake
transporters.
Finally, we have demonstrated that increased transporter activity in mixed
cultures under normoxic and normoglycemic conditions does not produce
neuronal injury (Fogal et al., 2005a). In fact, in pure astrocytes the enhancement
of transporter activity induced by IL-1β actually increases synthesis and export of
GSH, producing a net accumulation in extracellular GSH that is associated with
neuroprotection.
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Figure 6.1 Consequences of system xc- activity under physiological and
pathophysiological conditions. Under physiological conditions (normoxia and

normoglycemia; left panel), cystine transported into the cell via system xc- is
rapidly reduced and incorporated into GSH. IL-1β enhances the activity of the
transporter, which results in increased delivery of the rate-limiting substrate for
GSH synthesis and enhanced export of GSH into the extracellular space which
can protect pure astrocytes and mixed cortical cultures against tBOOH-mediated
toxicity. Under hypoxic conditions (middle panel), upregulation of system xc- by
IL-1β enhances the delivery of glutamate to the extracellular space. Hypoxia also
impairs EAAT/ system XAG- function leading to the net accumulation of glutamate
in the extracellular space which results in excitotoxic neuronal cell death.
Importantly, system xc- does not contribute to pure hypoxic neuronal injury (i.e.
neuronal cell death occurring under hypoxic conditions in the absence of IL-1β).
In contrast, under hypoglycemic conditions (right panel), the activity of system xcexpels glutamate into the extracellular space which initiates processes (currently
uncharacterized) that lead to the accumulation of extracellular glutamate. The
precise mechanism by which hypoglycemic neuronal injury occurs remains to be
elucidated, but neuronal cell death occurs independently of alterations in EAAT/
system xAG- activity and synaptically-derived neuronal glutamate. [Based on
results described herein as well as those found in (Fogal et al., 2005a; Fogal et
al., 2007).
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6.4

Hypoglycemic neuronal injury in the presence of competent

glutamate reuptake
What remains to be determined is precisely how system xc- induces
neuronal injury in the absence of impaired glutamate uptake as assessed via 3HD-aspartate uptake. This finding is consistent with the literature (Swanson and
Benington, 1996; Bakken et al., 1998), and estimates of glutamate reuptake
transporter expression suggest that 2,500 – 10,000 transporters per µm3 are
expressed in the brain (Bergles and Jahr, 1997; Lehre and Danbolt, 1998).
These high-affinity, highly expressed glutamate transporters should be able to
efficiently remove the glutamate that is fluxed through system xc-, especially
given the fact that glutamate transporters could theoretically reduce extracellular
glutamate to a concentration of ≈2 nM (Zerangue and Kavanaugh, 1996; Cavelier
et al., 2005). Based on studies by Wyatt and colleagues, heteroexchange via
system xc- is predicted to increase extracellular glutamate at a maximal rate of
0.6 µM/s (Cavelier et al., 2005), which is critically dependent on extracellular
cystine concentrations, the levels of which are disputed [estimates range from
0.13 µM reported in the nucleus accumbens (Baker et al., 2003), to 100-200 µM
which is routinely used in tissue culture studies (Murphy et al., 1989; Fogal et al.,
2005a; Fogal et al., 2007; Jackman et al., 2010)]. This begs the question are
there additional cellular sources of glutamate that contribute to injury or are the
techniques employed in our study not sensitive enough to detect changes in
glutamate uptake?

146

As mentioned previously, in vivo deafferentation experiments and in vitro
studies utilizing tetanus toxin implicate neuronal release of glutamate as
contributory to hypoglycemic neuronal injury (Wieloch et al., 1985; Monyer et al.,
1992). Yet in our hands, a concentration of tetanus toxin (300 ng/ml) that cleaves
neuronal synaptobrevin-2 and blocks depolarization-induced glutamate release
(Taylor and Hewett, 2002; Fogal et al., 2005b) — fails to attenuate neuronal
injury in this paradigm (Figure 3.1D). Further experimentation revealed that when
3 µg/ ml tetanus toxin (the highest concentration utilized by Monyer and
colleagues) was applied to our mixed cultures one day prior to glucose
deprivation there was some protection (15% neuronal protection), but it does not
recapitulate the robust finding of 40% neuronal protection reported in their
studies (Monyer et al., 1992). It suggests that there is a small contribution of
neuronally-derived glutamate to injury, yet still leaves room to consider additional
mechanisms of astrocytic glutamate release as participatory in hypoglycemic
neuronal cell death.

6.5

Future Directions
Logical future directions include elucidation of the molecular mechanisms

by which IL-1β regulates system xc- in astrocytes and to determine whether PKA
and PKC are involved in this process. Clearly, the finding that NF-κB inhibitors
enhance the expression of xCT mRNA is intriguing and deserves further
attention. Similarly, Nrf2, a known regulator of astrocytic xCT and other
antioxidant molecules (Sasaki et al., 2002; Lewerenz et al., 2009b), that requires
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PKC-mediated phosphorylation for activation (Huang et al., 2002; Numazawa et
al., 2003) should be examined closely as a candidate transcription factor
regulating the processes described herein.
Macroscopically, the biological relevance of this transporter to pathology in
the entire organism needs to be evaluated. As such, in vivo studies should be
carried out to characterize the role of energy deprivation-induced injury in sut/sut
mice following middle cerebral artery occlusion (MCAO) as a model of cerebral
ischemia and determine whether insulin-induced hypoglycemia in sut/sut mice
recapitulates the in vitro hypoglycemia findings. In vivo oxidative stress models
should be utilized to determine whether IL-1β can enhance GSH and/or confer
protection in vivo. However, discrepancies between in vivo and in vitro findings
may arise because animals have compensatory mechanisms which allow them
to thrive, whereas in vitro preparations require functional system xc- activity or a
reducing agent such as β-ME for survival. For example, one might hypothesize
that the loss of system xc- function would render animals more sensitive to
neuronal injury following MCAO due to reduced GSH levels. In fact, preliminary
data suggests the opposite and sut/sut mice appear to be protected against
ischemic injury (Figure 6.2). Interestingly, xCT-null mice do not have reduced
tissue GSH levels (Sato et al., 2005; Massie et al., 2010b; De Bundel et al.,
2011), although plasma GSH levels are reduced (Sato et al., 2005). Moreover,
recent work by Massie and colleagues demonstrates that the loss of system xcdoes not decrease striatal or hippocampal GSH levels and actually protects
neurons against 6-hydroxydopamine-induced injury and elevates the threshold
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for limbic seizures induced by intravenous infusion of kainate (an ionotropic
kainate glutamate receptor agonist) and pilocarpine (a muscarinic cholinergic
receptor agonist) or intraperitoneal administration of NMDA (an ionotropic
glutamate receptor agonist) in mutant mice (Massie et al., 2010b; De Bundel et
al., 2011). This paradoxical finding is attributed to the decrease in glutamate
release via system xc-, a mechanism that would also produce protection in the
setting of ischemia.
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Figure 6.2.
2. Comparison of ischemic brain damage between
wild-type and sut/sut mice. (A) Wild-type (WT; left) and sut/sut
mice (right) were subjected tto 45 minute reversible MCAO and
sacrificed
ed three days later. Brains were processed using TTC
staining as previously described (Fogal et al., 2007). The lack of
TTC staining (white areas, save for the corpus callosum)
represents infarcted tissue. Representative images of TTC-stained
TTC
coronal brain sections (2mm) from 2 animals of each genotype are
depicted. (B) Quantification of infarct size in the affected
hemisphere (HEMI), cortex, and caudate
caudate-putamen
putamen (CP) is shown
( n = 4 per genotype).
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6.6

System xc- as a therapeutic target
System xc- is an important biological transporter that has already been

utilized as a therapeutic target in the clinics. Sulfasalazine is a system xc- inhibitor
utilized for the treatment of inflammatory bowel diseases including Crohn’s
disease and ulcerative colitis, and rheumatoid arthritis (Linares et al., 2011). In
the immune system, the proliferation of T cells is regulated by antigen-presenting
cells such as dendritic cells and macrophages via the availability of the amino
acid cysteine (Gmunder et al., 1990; Angelini et al., 2002) because T cells lack
system xc- (Bannai, 1984b; Gmunder et al., 1991). Hence, reducing cysteine
delivery to T cells by inhibiting system xc- might be a useful strategy to limit
lymphocyte activation and related pathology in T-cell mediated autoimmune
diseases. Further, sulfasalazine and other system xc- inhibitors show promise as
adjuvant chemotherapeutics in certain cancers, including gliomas (Chung et al.,
2005; Lo et al., 2008; Savaskan et al., 2008; Chung and Sontheimer, 2009;
Pham et al., 2010). Whether inhibition of system xc- can limit excitotoxic neuronal
degeneration in humans remains to be ascertained, but preliminary experiments
in a model of experimental ischemia seem promising (see section 5.5) especially
in light of the findings that brain GSH levels are not compromised by loss of
system xc- function in vivo (Massie et al., 2010b; De Bundel et al., 2011).
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6.7

Overall significance
Neuroinflammation is a feature of a variety of neurological diseases and

disorders. While traditional views asserting that inflammation and the
inflammatory mediator IL-1β contribute to disease pathology in the CNS are
recapitulated in our model of inflammatory hypoxic neuronal injury, the data
contained in this dissertation demonstrate that IL-1β promotes GSH synthesis
and export which serves to protect both neurons and astrocytes against oxidative
injury. Understanding the regulation of system xc- by IL-1β could help to devise
strategies to harness the beneficial effects of system xc- to increase intracellular
GSH, and when appropriate, to reduce its activity to decrease the probability of
excitotoxic neuronal injury. Knowledge of the mechanisms by which one can
modulate system xc- activity and the resultant effects on neural physiology and
pathophysiology will continue to inform researchers and clinicians of the diverse
contributions of astrocytes and inflammation to health and disease states and
may guide the design of novel therapies that target astrocytes rather than
neurons.
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Supplemental Figure A1. Sut/sut astrocytes require βmercaptoethanol (β-ME) to support growth. Primary astrocyte
cultures were prepared from sut/sut mice as described in the methods.
One half of the cells were cultured in astrocyte plating media that was
supplemented with β-ME (55 µM), whereas the other half received
standard astrocyte plating media. Cells were incubated for eight (A) or
fifteen (B) days, after which MTT (3 ng/ml in PBS) was added to the
wells to assess cell viability (as described in section 4.3.7). Cell viability
was normalized to acidifed isopropanol alone (defined as 0 % cell
viability). n = 12.
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Supplemental Figure A2. Hypoxic neuronal cell death is reduced in
cultures containing sut/sut astrocytes derived from single pup
dissections. Chimeric mixed cortical cell cultures were obtained by
plating WT neurons on astrocytes derived from sut/sut mice (black bars).
These and control cultures (WT neurons on WT astrocytes; white bars)
were treated with 3 ng/ml IL-1β or vehicle for 20-24 hr, washed, and then
deprived of oxygen for 4-5 hr. The percentage of total neuronal cell
death was determined 20-24 hr later (n =6-9). An asterisk (*) indicates a
significant within-group difference, while a pound (#) sign indicates a
significant between-group difference as determined by a two-way
ANOVA followed by Bonferroni’s post hoc test. Significance was set at p
< 0.05.
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Supplemental Figure A3. Additional evidence that NF-κB may
negatively regulate xCT expression. Astrocytes (n=2) were incubated
with various concentrations of the NF-κB inhibitor, PDTC for 1 hour after
which IL-1β or vehicle was added for 6 hr then xCT mRNA assessed via
qPCR. Data are expressed as mean ± SEM fold change in xCT mRNA
compared to IL-1β-treated cells (set at 1).
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